index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
10501,Economic evaluation of different treatment modalities in acute kidney injury,"Major controversy exists regarding the preferred treatment option for acute kidney injury (AKI). The purpose of this study was to assess the incremental cost-effectiveness of continuous renal replacement therapy (CRRT) versus intermittent renal replacement therapy (IRRT) and conservative (CONS) AKI treatment in Belgium.An area-under-the-curve model based on survival analysis was used to estimate costs and health outcomes using a 2-year time horizon. Input data were derived from the multi-centre Stuivenberg Hospital Acute Renal Failure 4 study.Analyses indicated that in-hospital mortality, hospitalization costs and hospital length of stay differed significantly between treatment modes. Follow-up mortality rates and follow-up cost per day showed no significant difference between the treatment modes. Utility values, which improved gradually after admission to the hospital, revealed no significant differences between the three treatment strategies. CONS treatment was associated with a 2-year cost of 33,802? and 0.54 quality-adjusted life years (QALYs). The CRRT was the most expensive therapy with a cost of 51,365? leading to 0.57 QALYs. The cost and QALYs associated with IRRT were 43,445? and 0.50, respectively. One-way sensitivity analyses indicated the 'in-hospital mortality' as the variable with the greatest influence on the results. Probabilistic sensitivity analysis resulted in a significant difference in treatment costs but no significant difference in QALY gain.This study has indicated that the most expensive treatment (CRRT) associated with an incremental cost of approximately ?7920 generates only a minor non-significant increase in QALYs of 0.07 compared with IRRT. Additionally, the results revealed that the RRTs did not result in a significant increase in QALYs despite their higher cost compared with the CONS treatment. From a health economic perspective, the latter seems to be the preferred treatment strategy.",2012-01-10024,23144072,Nephrol Dial Transplant,Delphine M De Smedt,2012,27 / 11,4095-101,No,23144072,"Delphine M De Smedt; Monique M Elseviers; Robert L Lins; Lieven Annemans; Economic evaluation of different treatment modalities in acute kidney injury, Nephrol Dial Transplant, ; 27(11):0931-0509; 4095-101",QALY,Belgium,Not Stated,Not Stated,Intermittent renal replacement therapy (IRRT) vs. Conservative (CONS) acute kidney injury (AKI) treatment,Not Stated,Not Stated,19 Years,"Female, Male",Full,2 Years,3.00,Not Stated,-242896.72,Euro,2010,-381539.6
10502,Economic evaluation of different treatment modalities in acute kidney injury,"Major controversy exists regarding the preferred treatment option for acute kidney injury (AKI). The purpose of this study was to assess the incremental cost-effectiveness of continuous renal replacement therapy (CRRT) versus intermittent renal replacement therapy (IRRT) and conservative (CONS) AKI treatment in Belgium.An area-under-the-curve model based on survival analysis was used to estimate costs and health outcomes using a 2-year time horizon. Input data were derived from the multi-centre Stuivenberg Hospital Acute Renal Failure 4 study.Analyses indicated that in-hospital mortality, hospitalization costs and hospital length of stay differed significantly between treatment modes. Follow-up mortality rates and follow-up cost per day showed no significant difference between the treatment modes. Utility values, which improved gradually after admission to the hospital, revealed no significant differences between the three treatment strategies. CONS treatment was associated with a 2-year cost of 33,802? and 0.54 quality-adjusted life years (QALYs). The CRRT was the most expensive therapy with a cost of 51,365? leading to 0.57 QALYs. The cost and QALYs associated with IRRT were 43,445? and 0.50, respectively. One-way sensitivity analyses indicated the 'in-hospital mortality' as the variable with the greatest influence on the results. Probabilistic sensitivity analysis resulted in a significant difference in treatment costs but no significant difference in QALY gain.This study has indicated that the most expensive treatment (CRRT) associated with an incremental cost of approximately ?7920 generates only a minor non-significant increase in QALYs of 0.07 compared with IRRT. Additionally, the results revealed that the RRTs did not result in a significant increase in QALYs despite their higher cost compared with the CONS treatment. From a health economic perspective, the latter seems to be the preferred treatment strategy.",2012-01-10024,23144072,Nephrol Dial Transplant,Delphine M De Smedt,2012,27 / 11,4095-101,No,23144072,"Delphine M De Smedt; Monique M Elseviers; Robert L Lins; Lieven Annemans; Economic evaluation of different treatment modalities in acute kidney injury, Nephrol Dial Transplant, ; 27(11):0931-0509; 4095-101",QALY,Belgium,Not Stated,Not Stated,Continuous renal replacement therapy (CRRT) vs. Intermittent renal replacement therapy (CRRT),Not Stated,Not Stated,19 Years,"Female, Male",Full,2 Years,3.00,Not Stated,114012,Euro,2010,179088.84
10503,Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension,"Although angiotensin receptor blockers have different receptor binding properties, no comparative randomized studies with cardiovascular event endpoints have been performed for this class of drugs. The aim of this study was to assess the long-term cost-effectiveness of candesartan (Atacand(?)) versus generic losartan in the primary preventive treatment of hypertension.A decision-analytic model was developed to estimate costs and health outcomes over a patient's lifetime. Data from a clinical registry study were used to estimate event rates for cardiovascular complications, such as myocardial infarction and heart failure. Costs and quality of life data were from published sources. Costs were in Swedish kronor and the outcome was quality-adjusted life-years (QALYs).Due to reduced rates of cardiovascular complications, candesartan was associated with a QALY gain and lower health care costs compared with generic losartan (0.053 QALYs gained and reduced costs of approximately 4700 Swedish kronor for women; and 0.057 QALYs gained and reduced costs of approximately 4250 Swedish kronor for men). This result was robust in several sensitivity analyses.When modeling costs and health outcomes based on event rates for cardiovascular complications from a real-world registry study, candesartan appears to bring a QALY gain and a reduction in costs compared with generic losartan in the primary preventive treatment of hypertension in Sweden.",2012-01-10026,23144565,Clinicoecon Outcomes Res,Ola Granstr?m,2012,4 /,313-22,No,23144565,"Ola Granstr?m; Lars-?ke Levin; Martin Henriksson; Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension, Clinicoecon Outcomes Res , ; 4 ():1178-6981; 313-22",QALY,Sweden,Not Stated,Not Stated,Candesartan vs. Losartan,Not Stated,Not Stated,Not Stated,Male,Full,Lifetime,3.00,3.00,-74719.3,Sweden,2011,-13267.49
10504,Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension,"Although angiotensin receptor blockers have different receptor binding properties, no comparative randomized studies with cardiovascular event endpoints have been performed for this class of drugs. The aim of this study was to assess the long-term cost-effectiveness of candesartan (Atacand(?)) versus generic losartan in the primary preventive treatment of hypertension.A decision-analytic model was developed to estimate costs and health outcomes over a patient's lifetime. Data from a clinical registry study were used to estimate event rates for cardiovascular complications, such as myocardial infarction and heart failure. Costs and quality of life data were from published sources. Costs were in Swedish kronor and the outcome was quality-adjusted life-years (QALYs).Due to reduced rates of cardiovascular complications, candesartan was associated with a QALY gain and lower health care costs compared with generic losartan (0.053 QALYs gained and reduced costs of approximately 4700 Swedish kronor for women; and 0.057 QALYs gained and reduced costs of approximately 4250 Swedish kronor for men). This result was robust in several sensitivity analyses.When modeling costs and health outcomes based on event rates for cardiovascular complications from a real-world registry study, candesartan appears to bring a QALY gain and a reduction in costs compared with generic losartan in the primary preventive treatment of hypertension in Sweden.",2012-01-10026,23144565,Clinicoecon Outcomes Res,Ola Granstr?m,2012,4 /,313-22,No,23144565,"Ola Granstr?m; Lars-?ke Levin; Martin Henriksson; Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension, Clinicoecon Outcomes Res , ; 4 ():1178-6981; 313-22",QALY,Sweden,Not Stated,Not Stated,Candesartan vs. Losartan,Not Stated,Not Stated,Not Stated,Female,Full,Lifetime,3.00,3.00,-88528.3,Sweden,2011,-15719.48
10505,An exercise intervention to prevent falls in Parkinson's: an economic evaluation,"ABSTRACT: BACKGROUND: People with Parkinson's (PwP) experience frequent and recurrent falls. As these falls may have devastating consequences, there is an urgent need to identify cost-effective interventions with the potential to reduce falls in PwP. The purpose of this economic evaluation is to compare the costs and cost-effectiveness of a targeted exercise programme versus usual care for PwP who were at risk of falling. METHODS: One hundred and thirty participants were recruited through specialist clinics, primary care and Parkinson's support groups and randomised to either an exercise intervention or usual care. Health and social care utilisation and health-related quality of life (EQ-5D) were assessed over the 20 weeks of the study (ten-week intervention period and ten-week follow up period), and these data were complete for 93 participants. Incremental cost per quality adjusted life year (QALY) was estimated. The uncertainty around costs and QALYs was represented using cost-effectiveness acceptability curves. RESULTS: The mean cost of the intervention was [pound sign]76 per participant. Although in direction of favour of exercise intervention, there was no statistically significant differences between groups in total healthcare (-[pound sign]128, 95% CI: -734 to 478), combined health and social care costs ([pound sign]-35, 95% CI: -817 to 746) or QALYs (0.03, 95% CI: -0.02 to 0.03) at 20 weeks. Nevertheless, exploration of the uncertainty surrounding these estimates suggests there is more than 80% probability that the exercise intervention is a cost-effective strategy relative to usual care. CONCLUSION: Whilst we found no difference between groups in total healthcare, total social care cost and QALYs, analyses indicate that there is high probability that the exercise intervention is cost-effective compared with usual care. These results require confirmation by larger trial-based economic evaluations and over the longer term.",2012-01-10069,23176532,BMC Health Serv Res,Emily Fletcher,2012,12 / 1,426,Yes,23176532,"Emily Fletcher; Victoria A Goodwin; Suzanne H Richards; John L Campbell; Rod S Taylor; An exercise intervention to prevent falls in Parkinson's: an economic evaluation, BMC Health Serv Res, Nov/23/2012; 12(1):1472-6963; 426",QALY,Not Stated,Not Stated,Not Stated,Targeted exercise program vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Weeks,Not Stated,Not Stated,-1166.67,United Kingdom,2008,-2600.77
10506,An exercise intervention to prevent falls in Parkinson's: an economic evaluation,"ABSTRACT: BACKGROUND: People with Parkinson's (PwP) experience frequent and recurrent falls. As these falls may have devastating consequences, there is an urgent need to identify cost-effective interventions with the potential to reduce falls in PwP. The purpose of this economic evaluation is to compare the costs and cost-effectiveness of a targeted exercise programme versus usual care for PwP who were at risk of falling. METHODS: One hundred and thirty participants were recruited through specialist clinics, primary care and Parkinson's support groups and randomised to either an exercise intervention or usual care. Health and social care utilisation and health-related quality of life (EQ-5D) were assessed over the 20 weeks of the study (ten-week intervention period and ten-week follow up period), and these data were complete for 93 participants. Incremental cost per quality adjusted life year (QALY) was estimated. The uncertainty around costs and QALYs was represented using cost-effectiveness acceptability curves. RESULTS: The mean cost of the intervention was [pound sign]76 per participant. Although in direction of favour of exercise intervention, there was no statistically significant differences between groups in total healthcare (-[pound sign]128, 95% CI: -734 to 478), combined health and social care costs ([pound sign]-35, 95% CI: -817 to 746) or QALYs (0.03, 95% CI: -0.02 to 0.03) at 20 weeks. Nevertheless, exploration of the uncertainty surrounding these estimates suggests there is more than 80% probability that the exercise intervention is a cost-effective strategy relative to usual care. CONCLUSION: Whilst we found no difference between groups in total healthcare, total social care cost and QALYs, analyses indicate that there is high probability that the exercise intervention is cost-effective compared with usual care. These results require confirmation by larger trial-based economic evaluations and over the longer term.",2012-01-10069,23176532,BMC Health Serv Res,Emily Fletcher,2012,12 / 1,426,Yes,23176532,"Emily Fletcher; Victoria A Goodwin; Suzanne H Richards; John L Campbell; Rod S Taylor; An exercise intervention to prevent falls in Parkinson's: an economic evaluation, BMC Health Serv Res, Nov/23/2012; 12(1):1472-6963; 426",QALY,Not Stated,Not Stated,Not Stated,Targeted exercise program vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Weeks,Not Stated,Not Stated,-4066.67,United Kingdom,2008,-9065.53
10507,Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information,"OBJECTIVES: A high prevalence of Coeliac Disease (CD) is found among patients with a clinical diagnosis of irritable bowel syndrome (IBS) compared to the general population. Symptoms of CD are quite similar to IBS, but its treatment is different. The aim of this study was to evaluate the cost-effectiveness of screening for CD in patients with diarrhoea/mixed type IBS (IBS-D/mix) in terms of cost per quality adjusted life year (QALY) in the Netherlands. METHODS: A decision model was constructed to evaluate the costs and health benefits of serological testing followed by confirmatory endoscopy with biopsy. Probabilistic sensitivity analysis (PSA) was performed to examine the effect of parameter uncertainty. Finally, the budget impact of implementing the screening process was also computed for implementation over a 10-year time horizon. RESULTS: Screening resulted in an increase of about 0.07 quality life years (QALYs) per patient over a lifetime horizon. The incremental cost effectiveness ratio was about 6,200 euro/QALY compared to no screening. The PSA showed that the uncertainty in cost effectiveness results is not considerable. The value of information analysis confirmed the robustness of the results. Screening all current patients with diarrhea/mixed type IBS would require a total budget of about 25 million Euros over a 10 year time period. CONCLUSION: Screening patients with IBS-D or IBS-mix for CD is almost certainly cost-effective. The screening program would improve the quality of life of those patients with IBS symptoms who actually have CD at a relatively low cost.",2012-01-10073,23179163,Eur J Health Econ,Leyla Mohseninejad,2013,14 / 6,,Yes,23179163,"Leyla Mohseninejad; Talitha Feenstra; Henriette E van der Horst; Helen Woutersen-Koch; Erik Buskens; Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information, Eur J Health Econ, ; 14(6):1618-7598",QALY,Netherlands,Not Stated,Not Stated,Screening of patients with IBS-D or mix type symptoms and subsequent treatment for celiac disease vs. Standard of care (no screening for celiac disease),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,4.00,1.50,6200,Euro,2009,10423.03
10508,Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information,"OBJECTIVES: A high prevalence of Coeliac Disease (CD) is found among patients with a clinical diagnosis of irritable bowel syndrome (IBS) compared to the general population. Symptoms of CD are quite similar to IBS, but its treatment is different. The aim of this study was to evaluate the cost-effectiveness of screening for CD in patients with diarrhoea/mixed type IBS (IBS-D/mix) in terms of cost per quality adjusted life year (QALY) in the Netherlands. METHODS: A decision model was constructed to evaluate the costs and health benefits of serological testing followed by confirmatory endoscopy with biopsy. Probabilistic sensitivity analysis (PSA) was performed to examine the effect of parameter uncertainty. Finally, the budget impact of implementing the screening process was also computed for implementation over a 10-year time horizon. RESULTS: Screening resulted in an increase of about 0.07 quality life years (QALYs) per patient over a lifetime horizon. The incremental cost effectiveness ratio was about 6,200 euro/QALY compared to no screening. The PSA showed that the uncertainty in cost effectiveness results is not considerable. The value of information analysis confirmed the robustness of the results. Screening all current patients with diarrhea/mixed type IBS would require a total budget of about 25 million Euros over a 10 year time period. CONCLUSION: Screening patients with IBS-D or IBS-mix for CD is almost certainly cost-effective. The screening program would improve the quality of life of those patients with IBS symptoms who actually have CD at a relatively low cost.",2012-01-10073,23179163,Eur J Health Econ,Leyla Mohseninejad,2013,14 / 6,,Yes,23179163,"Leyla Mohseninejad; Talitha Feenstra; Henriette E van der Horst; Helen Woutersen-Koch; Erik Buskens; Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information, Eur J Health Econ, ; 14(6):1618-7598",QALY,Netherlands,Not Stated,Not Stated,Screening in patients with all IBS symptoms vs. Standard of care (no screening for celiac disease),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,4.00,1.50,6500,Euro,2009,10927.37
10509,Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information,"OBJECTIVES: A high prevalence of Coeliac Disease (CD) is found among patients with a clinical diagnosis of irritable bowel syndrome (IBS) compared to the general population. Symptoms of CD are quite similar to IBS, but its treatment is different. The aim of this study was to evaluate the cost-effectiveness of screening for CD in patients with diarrhoea/mixed type IBS (IBS-D/mix) in terms of cost per quality adjusted life year (QALY) in the Netherlands. METHODS: A decision model was constructed to evaluate the costs and health benefits of serological testing followed by confirmatory endoscopy with biopsy. Probabilistic sensitivity analysis (PSA) was performed to examine the effect of parameter uncertainty. Finally, the budget impact of implementing the screening process was also computed for implementation over a 10-year time horizon. RESULTS: Screening resulted in an increase of about 0.07 quality life years (QALYs) per patient over a lifetime horizon. The incremental cost effectiveness ratio was about 6,200 euro/QALY compared to no screening. The PSA showed that the uncertainty in cost effectiveness results is not considerable. The value of information analysis confirmed the robustness of the results. Screening all current patients with diarrhea/mixed type IBS would require a total budget of about 25 million Euros over a 10 year time period. CONCLUSION: Screening patients with IBS-D or IBS-mix for CD is almost certainly cost-effective. The screening program would improve the quality of life of those patients with IBS symptoms who actually have CD at a relatively low cost.",2012-01-10073,23179163,Eur J Health Econ,Leyla Mohseninejad,2013,14 / 6,,Yes,23179163,"Leyla Mohseninejad; Talitha Feenstra; Henriette E van der Horst; Helen Woutersen-Koch; Erik Buskens; Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information, Eur J Health Econ, ; 14(6):1618-7598",QALY,Netherlands,Not Stated,Not Stated,Screening in patients with all IBS symptoms vs. Screening in patients with all IBSdiarrhea and mixed-type (IBS-D/mix),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,4.00,1.50,27300,Euro,2009,45894.95
10510,Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information,"OBJECTIVES: A high prevalence of Coeliac Disease (CD) is found among patients with a clinical diagnosis of irritable bowel syndrome (IBS) compared to the general population. Symptoms of CD are quite similar to IBS, but its treatment is different. The aim of this study was to evaluate the cost-effectiveness of screening for CD in patients with diarrhoea/mixed type IBS (IBS-D/mix) in terms of cost per quality adjusted life year (QALY) in the Netherlands. METHODS: A decision model was constructed to evaluate the costs and health benefits of serological testing followed by confirmatory endoscopy with biopsy. Probabilistic sensitivity analysis (PSA) was performed to examine the effect of parameter uncertainty. Finally, the budget impact of implementing the screening process was also computed for implementation over a 10-year time horizon. RESULTS: Screening resulted in an increase of about 0.07 quality life years (QALYs) per patient over a lifetime horizon. The incremental cost effectiveness ratio was about 6,200 euro/QALY compared to no screening. The PSA showed that the uncertainty in cost effectiveness results is not considerable. The value of information analysis confirmed the robustness of the results. Screening all current patients with diarrhea/mixed type IBS would require a total budget of about 25 million Euros over a 10 year time period. CONCLUSION: Screening patients with IBS-D or IBS-mix for CD is almost certainly cost-effective. The screening program would improve the quality of life of those patients with IBS symptoms who actually have CD at a relatively low cost.",2012-01-10073,23179163,Eur J Health Econ,Leyla Mohseninejad,2013,14 / 6,,Yes,23179163,"Leyla Mohseninejad; Talitha Feenstra; Henriette E van der Horst; Helen Woutersen-Koch; Erik Buskens; Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information, Eur J Health Econ, ; 14(6):1618-7598",QALY,Netherlands,Not Stated,Not Stated,Double-testing strategy for celiac disease in patients with all IBS symptoms (includes a second blood test (Endomysial antibody (EMA)) in combination with tissue transglutaminase antibody (tTG)) vs. Standard of care (no screening for celiac disease),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,4.00,1.50,6800,Euro,2009,11431.71
10511,A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin,"As healthcare spending on diabetes and its complications continues to rise, the optimization of prescribed insulin regimens is becoming increasingly important from both clinical and economic perspectives. The aim of the present study was to evaluate the costeffectiveness of 75/25 biphasic insulin lispro and 50/50 biphasic insulin lispro (Humalog? Mix75/25 and Humalog? Mix50/50, respectively; Eli Lilly and Company, Indianapolis, IN, USA) compared with a long-acting analog insulin regimen in patients with type 2 diabetes.A published and validated computer simulation model of diabetes was used to evaluate the cost-effectiveness of 75/25 and 50/50 biphasic insulin lispro versus a longacting analog insulin (insulin glargine) from the perspective of a healthcare payer in the UK. Treatment effects in terms of glycated hemoglobin (HbA(1c)) benefits were taken from a recent meta-analysis. Direct medical costs including pharmacy, complication, and patient management costs were obtained from published sources. All costs were expressed in 2008 British pounds sterling (GBP), and future costs and clinical benefits were discounted at 3.5% per annum. Sensitivity analyses were performed.75/25 and 50/50 biphasic insulin lispro were associated with improvements in life expectancy of 0.09 and 0.13 years, respectively, improvements in quality-adjusted life expectancy of 0.09 quality-adjusted life years (QALYs) and 0.12 QALYs, respectively, and reductions in cost of GBP 1,217 and GBP 430, respectively, when compared with long-acting analog insulin.Based on a recently published metaanalysis, biphasic analog insulins are likely to improve clinical outcomes and reduce costs versus long-acting analog insulins in the longterm treatment of patients with type 2 diabetes in the UK.",2012-01-10075,23179373,Adv Ther,Richard F Pollock,2012,29 / 12,1051-66,No,23179373,"Richard F Pollock; Bradley H Curtis; Jayne Smith-Palmer; William J Valentine; A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin, Adv Ther, ; 29(12):0741-238X; 1051-66",QALY,Not Stated,Not Stated,Not Stated,70/25 biphasic insulin lispro vs. Long-acting insulin analog,Not Stated,Not Stated,Not Stated,"Female, Male",Full,35 Years,3.50,3.50,-13522.22,United Kingdom,2008,-30144.14
10512,A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin,"As healthcare spending on diabetes and its complications continues to rise, the optimization of prescribed insulin regimens is becoming increasingly important from both clinical and economic perspectives. The aim of the present study was to evaluate the costeffectiveness of 75/25 biphasic insulin lispro and 50/50 biphasic insulin lispro (Humalog? Mix75/25 and Humalog? Mix50/50, respectively; Eli Lilly and Company, Indianapolis, IN, USA) compared with a long-acting analog insulin regimen in patients with type 2 diabetes.A published and validated computer simulation model of diabetes was used to evaluate the cost-effectiveness of 75/25 and 50/50 biphasic insulin lispro versus a longacting analog insulin (insulin glargine) from the perspective of a healthcare payer in the UK. Treatment effects in terms of glycated hemoglobin (HbA(1c)) benefits were taken from a recent meta-analysis. Direct medical costs including pharmacy, complication, and patient management costs were obtained from published sources. All costs were expressed in 2008 British pounds sterling (GBP), and future costs and clinical benefits were discounted at 3.5% per annum. Sensitivity analyses were performed.75/25 and 50/50 biphasic insulin lispro were associated with improvements in life expectancy of 0.09 and 0.13 years, respectively, improvements in quality-adjusted life expectancy of 0.09 quality-adjusted life years (QALYs) and 0.12 QALYs, respectively, and reductions in cost of GBP 1,217 and GBP 430, respectively, when compared with long-acting analog insulin.Based on a recently published metaanalysis, biphasic analog insulins are likely to improve clinical outcomes and reduce costs versus long-acting analog insulins in the longterm treatment of patients with type 2 diabetes in the UK.",2012-01-10075,23179373,Adv Ther,Richard F Pollock,2012,29 / 12,1051-66,No,23179373,"Richard F Pollock; Bradley H Curtis; Jayne Smith-Palmer; William J Valentine; A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin, Adv Ther, ; 29(12):0741-238X; 1051-66",QALY,Not Stated,Not Stated,Not Stated,50/50 biphasic insulin lispro vs. Long-acting insulin analog,Not Stated,Not Stated,Not Stated,"Female, Male",Full,35 Years,3.50,3.50,-3583.33,United Kingdom,2008,-7988.07
10513,Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland,"The objective of this study was to estimate the potential budget impact and cost-effectiveness of the combination treatment of a cholinesterase inhibitor and memantine in Switzerland.The prevalence of dementia according to European sources and future Swiss population data were used to estimate the number of patients with Alzheimer's dementia in Switzerland. Both direct and indirect costs calculated from Swiss sources were included. Utility estimates and transition probabilities were obtained from the published literature. A Markov model was used for the cost-utility analysis in order to calculate incremental cost-effectiveness ratios from a health care and a societal perspective.Assuming mono treatment (either a cholinesterase inhibitor or memantine), treatment costs would increase from CHF 22.7 million in 2012 to CHF 26.1 million in 2016, the additional yearly treatment costs for the combination treatment (cholinesterase inhibitor and memantine) would be between CHF 1.7 million and CHF 1.9 million. The Markov model compared health care costs of the mono treatment to costs of the combination treatment over five years. From a health care perspective, the combination treatment saved CHF 27,655 per patient over five years and CHF 248,895/quality adjusted life year compared to the mono treatment.Implementation of the reimbursed combination treatment would incur additional treatment costs of about CHF 10 million over five years. From a health care perspective, the combination treatment would decrease costs over five years by CHF 50 million. Based on long term considerations, the combination treatment was the dominant strategy over the mono treatment.",2012-01-10076,23180021,Swiss Med Wkly,Alena M Pfeil,2012,142 /,w13676,No,23180021,"Alena M Pfeil; Reto W Kressig; Thomas D Szucs; Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland, Swiss Med Wkly, ; 142 ():1424-7860; w13676",QALY,Not Stated,Not Stated,Not Stated,Memantine and cholinesterase inhibitor vs. Cholinesterase inhibitor,Not Stated,Not Stated,Not Stated,"Female, Male",Full,7 Years,3.00,3.00,-230466.67,Switzerland,2011,-300376.9
10514,Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland,"The objective of this study was to estimate the potential budget impact and cost-effectiveness of the combination treatment of a cholinesterase inhibitor and memantine in Switzerland.The prevalence of dementia according to European sources and future Swiss population data were used to estimate the number of patients with Alzheimer's dementia in Switzerland. Both direct and indirect costs calculated from Swiss sources were included. Utility estimates and transition probabilities were obtained from the published literature. A Markov model was used for the cost-utility analysis in order to calculate incremental cost-effectiveness ratios from a health care and a societal perspective.Assuming mono treatment (either a cholinesterase inhibitor or memantine), treatment costs would increase from CHF 22.7 million in 2012 to CHF 26.1 million in 2016, the additional yearly treatment costs for the combination treatment (cholinesterase inhibitor and memantine) would be between CHF 1.7 million and CHF 1.9 million. The Markov model compared health care costs of the mono treatment to costs of the combination treatment over five years. From a health care perspective, the combination treatment saved CHF 27,655 per patient over five years and CHF 248,895/quality adjusted life year compared to the mono treatment.Implementation of the reimbursed combination treatment would incur additional treatment costs of about CHF 10 million over five years. From a health care perspective, the combination treatment would decrease costs over five years by CHF 50 million. Based on long term considerations, the combination treatment was the dominant strategy over the mono treatment.",2012-01-10076,23180021,Swiss Med Wkly,Alena M Pfeil,2012,142 /,w13676,No,23180021,"Alena M Pfeil; Reto W Kressig; Thomas D Szucs; Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland, Swiss Med Wkly, ; 142 ():1424-7860; w13676",QALY,Not Stated,Not Stated,Not Stated,Memantine and cholinesterase inhibitor vs. Cholinesterase inhibitor,Not Stated,Not Stated,Not Stated,"Female, Male",Full,7 Years,3.00,3.00,-39833.34,Switzerland,2011,-51916.46
10515,"Rehabilitation in advanced, progressive, recurrent cancer: a randomized controlled trial","CONTEXT: Two million people across the U.K. are living with cancer, often experienced as a long-term condition. They may have unmet needs after active treatment. Rehabilitation aims to address these needs, maximize psychological and physical function, and enable minimum dependency regardless of life expectancy. OBJECTIVES: We aimed to test, in a randomized controlled trial, the clinical and cost effectiveness of a rehabilitation intervention for patients with advanced, recurrent cancer. METHODS: We conducted a two-arm, wait-list control, randomized trial of a complex rehabilitation intervention delivered by a hospice-based multidisciplinary team vs. usual care for active, progressive, recurrent hematological and breast malignancies, with a follow-up at three months. The primary outcome was the psychological subscale of the Supportive Care Needs Survey (SCNS). Secondary outcomes were other domains of the SCNS, psychological status, continuity of care, quality of life, and resource use. RESULTS: Forty-one participants were enrolled and 36 completed the trial. The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006). The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly. The incremental cost-effectiveness ratio was pound19,390 per quality-adjusted life year. CONCLUSION: This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective. Despite small numbers, the main effect size was robust. We recommend implementation alongside evaluation in wider clinical settings and patient populations.",2012-01-10081,23182307,J Pain Symptom Manage,Louise Jones,2013,46 / 3,,No,23182307,"Louise Jones; Gail Fitzgerald; Baptiste Leurent; Jeffrey Round; Jane Eades; Sarah Davis; Faye Gishen; Amanda Holman; Katherine Hopkins; Adrian Tookman; Rehabilitation in advanced, progressive, recurrent cancer: a randomized controlled trial, J Pain Symptom Manage, 2013 Sep; 46(3):0885-3924",QALY,Not Stated,Not Stated,Not Stated,Complex rehabilitation intervention delivered by a hospice-based multidisciplinary team vs. Usual care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,19391,United Kingdom,2010,35530.55
10516,Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment : an exploratory economic evaluation of personalized medicine,"To evaluate the cost effectiveness of genetic screening for the apolipoprotein (APOE) e4 allele in combination with preventive donepezil treatment in comparison with the standard of care for amnestic mild cognitive impairment (AMCI) patients in Canada.We performed a cost-effectiveness analysis using a Markov model with a societal perspective and a time horizon of 30?years. For each strategy, we calculated quality-adjusted life-years (QALYs), using utilities from the literature. Costs were also based on the literature and, when appropriate, Ontario sources. One-way and probabilistic sensitivity analyses were performed. Expected value of perfect information (EVPI) analysis was conducted to explore the value of future research.The base case results in our exploratory study suggest that the combination of genetic testing and preventive donepezil treatment resulted in a gain of 0.027 QALYs and an incremental cost of $1,015 (in 2009 Canadian dollars [Can$]), compared with the standard of care. The incremental cost-effectiveness ratio (ICER) for the base case was Can$38,016 per QALY. The ICER was sensitive to the effectiveness of donepezil in slowing the rate of progression to Alzheimer's disease (AD), utility in AMCI patients, and AD and donepezil treatment costs. EVPI analysis showed that additional information on these parameters would be of value.Using presently available clinical evidence, this exploratory study illustrates that genetic testing combined with preventive donepezil treatment for AMCI patients may be economically attractive. Since our results were based on a secondary post hoc analysis, our study alone is insufficient to warrant recommending APOE genotyping in AMCI patients. Future research on the effectiveness of preventive donepezil as a targeted therapy is recommended.",2012-01-10088,23188525,Mol Diagn Ther,Sandjar Djalalov,2012,16 / 6,389-99,No,23188525,"Sandjar Djalalov; Jean Yong; Jaclyn Beca; Sandra Black; Gustavo Saposnik; Zahra Musa; Katherine Siminovitch; Myla Moretti; Jeffrey S Hoch; Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment : an exploratory economic evaluation of personalized medicine, Mol Diagn Ther, ; 16(6):1177-1062; 389-99",QALY,Not Stated,Not Stated,Not Stated,Screening for apolipoprotein (APOE) E4 followed by donepezil in carriers and non-carriers monitoried until development of Alzheimer's disease vs. Standard of care (monitored until Alzheimer's disease progression),Not Stated,70 Years,70 Years,"Female, Male",Full,Lifetime,5.00,5.00,38016,Canada,2009,40373.68
10517,Cost-effectiveness of lumbar artificial intervertebral disc replacement: driven by the choice of comparator,"BACKGROUND: Lower back pain is a common and costly condition in Australia. This paper aims to conduct an economic evaluation of lumbar artificial intervertebral disc replacement (AIDR) compared with lumbar fusion for the treatment of patients suffering from significant axial back pain and/or radicular (nerve root) pain, secondary to disc degeneration or prolapse, who have failed conservative treatment. METHODS: A cost-effectiveness approach was used to compare costs and benefits of AIDR to five fusion approaches. Resource use was based on Medicare Benefits Schedule claims data and expert opinion. Effectiveness and re-operation rates were based on published randomized controlled trials. The key clinical outcomes considered were narcotic medication discontinuation, achievement of overall clinical success, achievement of Oswestry Disability Index success and quality-adjusted life-years gained. RESULTS: AIDR was estimated to be cost-saving compared with fusion overall ($1600/patient); however, anterior lumbar interbody fusion and posterolateral fusion were less costly by $2155 and $807, respectively. The incremental cost-effectiveness depends on the outcome considered and the comparator. CONCLUSIONS: AIDR is potentially a cost-saving treatment for lumbar disc degeneration, although longer-term follow-up data are required to substantiate this claim. The incremental cost-effectiveness depends on the outcome considered and the comparator, and further research is required before any firm conclusions can be drawn.",2012-01-10089,23190445,ANZ J Surg,Bonny Parkinson,2013,83 / 9,,No,23190445,"Bonny Parkinson; Stephen Goodall; Prema Thavaneswaran; Cost-effectiveness of lumbar artificial intervertebral disc replacement: driven by the choice of comparator, ANZ J Surg, 2013 Sep; 83(9):1445-1433",QALY,Australia,Not Stated,Not Stated,Posterior lumbar interbody fusion (PLIF) vs. Artificial intervertebral disc replacement (AIDR),Not Stated,Not Stated,Not Stated,"Female, Male",Full,2 Years,Not Stated,Not Stated,464000,Australia,2011,551617.99
10518,Cost-effectiveness of lumbar artificial intervertebral disc replacement: driven by the choice of comparator,"BACKGROUND: Lower back pain is a common and costly condition in Australia. This paper aims to conduct an economic evaluation of lumbar artificial intervertebral disc replacement (AIDR) compared with lumbar fusion for the treatment of patients suffering from significant axial back pain and/or radicular (nerve root) pain, secondary to disc degeneration or prolapse, who have failed conservative treatment. METHODS: A cost-effectiveness approach was used to compare costs and benefits of AIDR to five fusion approaches. Resource use was based on Medicare Benefits Schedule claims data and expert opinion. Effectiveness and re-operation rates were based on published randomized controlled trials. The key clinical outcomes considered were narcotic medication discontinuation, achievement of overall clinical success, achievement of Oswestry Disability Index success and quality-adjusted life-years gained. RESULTS: AIDR was estimated to be cost-saving compared with fusion overall ($1600/patient); however, anterior lumbar interbody fusion and posterolateral fusion were less costly by $2155 and $807, respectively. The incremental cost-effectiveness depends on the outcome considered and the comparator. CONCLUSIONS: AIDR is potentially a cost-saving treatment for lumbar disc degeneration, although longer-term follow-up data are required to substantiate this claim. The incremental cost-effectiveness depends on the outcome considered and the comparator, and further research is required before any firm conclusions can be drawn.",2012-01-10089,23190445,ANZ J Surg,Bonny Parkinson,2013,83 / 9,,No,23190445,"Bonny Parkinson; Stephen Goodall; Prema Thavaneswaran; Cost-effectiveness of lumbar artificial intervertebral disc replacement: driven by the choice of comparator, ANZ J Surg, 2013 Sep; 83(9):1445-1433",QALY,Australia,Not Stated,Not Stated,Posterolateral fusion (PLF) vs. Artificial intervertebral disc replacement (AIDR),Not Stated,Not Stated,Not Stated,"Female, Male",Full,2 Years,Not Stated,Not Stated,-80700,Australia,2011,-95938.73
10519,Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis,"Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time. Please see later in the article for the Editors' Summary.",2012-01-10107,23209384,PLoS Med,Daniel E Winetsky,2012,9 / 11,e1001348,No,23209384,"Daniel E Winetsky; Diana M Negoescu; Emilia H Demarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis, PLoS Med, ; 9(11):1549-1676; e1001348",QALY,Not Stated,Not Stated,Not Stated,Sputum polymerase chain reaction (PCR) screening vs. Mass miniature radiography (MMR) with sputum PCR detection of multidrug resistant-tuberculosis (MDR-TB),Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,543,United States,2009,655.06
10520,Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis,"Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time. Please see later in the article for the Editors' Summary.",2012-01-10107,23209384,PLoS Med,Daniel E Winetsky,2012,9 / 11,e1001348,No,23209384,"Daniel E Winetsky; Diana M Negoescu; Emilia H Demarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis, PLoS Med, ; 9(11):1549-1676; e1001348",QALY,Not Stated,Not Stated,Not Stated,Mass miniature radiography (MMR) with sputum polymerase chain reaction (PCR) detection of multidrug resistant-tuberculosis (MDR-TB) vs. Standard of care (mass miniature radiography (MMR) screening),Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-273.12,United States,2009,-329.48
10521,Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis,"Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time. Please see later in the article for the Editors' Summary.",2012-01-10107,23209384,PLoS Med,Daniel E Winetsky,2012,9 / 11,e1001348,No,23209384,"Daniel E Winetsky; Diana M Negoescu; Emilia H Demarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis, PLoS Med, ; 9(11):1549-1676; e1001348",QALY,Not Stated,Not Stated,Not Stated,Sputum polymerase chain reaction (PCR) screening vs. Combined mass miniature radiography (MMR) and symptom screening,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,87,United States,2009,104.95
10522,Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis,"Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time. Please see later in the article for the Editors' Summary.",2012-01-10107,23209384,PLoS Med,Daniel E Winetsky,2012,9 / 11,e1001348,No,23209384,"Daniel E Winetsky; Diana M Negoescu; Emilia H Demarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis, PLoS Med, ; 9(11):1549-1676; e1001348",QALY,Not Stated,Not Stated,Not Stated,Combined mass miniature radiography (MMR) and symptom screening vs. Standard of care (mass miniature radiography (MMR) screening),Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-203.35,United States,2009,-245.32
10523,Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis,"Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time. Please see later in the article for the Editors' Summary.",2012-01-10107,23209384,PLoS Med,Daniel E Winetsky,2012,9 / 11,e1001348,No,23209384,"Daniel E Winetsky; Diana M Negoescu; Emilia H Demarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis, PLoS Med, ; 9(11):1549-1676; e1001348",QALY,Not Stated,Not Stated,Not Stated,Mass miniature radiography (MMR) with sputum polymerase chain reaction (PCR) detection of multidrug resistant-tuberculosis (MDR-TB) vs. Standard of care (mass miniature radiography (MMR) screening),Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-234.59,United States,2009,-283
10524,Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis,"Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time. Please see later in the article for the Editors' Summary.",2012-01-10107,23209384,PLoS Med,Daniel E Winetsky,2012,9 / 11,e1001348,No,23209384,"Daniel E Winetsky; Diana M Negoescu; Emilia H Demarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis, PLoS Med, ; 9(11):1549-1676; e1001348",QALY,Not Stated,Not Stated,Not Stated,Sputum polymerase chain reaction (PCR) screening vs. Mass miniature radiography (MMR) with sputum PCR detection of multidrug resistant-tuberculosis (MDR-TB),Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,1569,United States,2009,1892.79
10525,Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis,"Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time. Please see later in the article for the Editors' Summary.",2012-01-10107,23209384,PLoS Med,Daniel E Winetsky,2012,9 / 11,e1001348,No,23209384,"Daniel E Winetsky; Diana M Negoescu; Emilia H Demarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis, PLoS Med, ; 9(11):1549-1676; e1001348",QALY,Not Stated,Not Stated,Not Stated,Mass miniature radiography (MMR) with sputum polymerase chain reaction (PCR) detection of multidrug resistant-tuberculosis (MDR-TB) vs. Standard of care (mass miniature radiography (MMR) screening),Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,135,United States,2009,162.86
10526,Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis,"Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time. Please see later in the article for the Editors' Summary.",2012-01-10107,23209384,PLoS Med,Daniel E Winetsky,2012,9 / 11,e1001348,No,23209384,"Daniel E Winetsky; Diana M Negoescu; Emilia H Demarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis, PLoS Med, ; 9(11):1549-1676; e1001348",QALY,Not Stated,Not Stated,Not Stated,Standard of care (mass miniature radiography (MMR) screening) vs. Self-referral for tuberculosis,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,26,United States,2009,31.37
10527,Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis,"Prisons of the former Soviet Union (FSU) have high rates of multidrug-resistant tuberculosis (MDR-TB) and are thought to drive general population tuberculosis (TB) epidemics. Effective prison case detection, though employing more expensive technologies, may reduce long-term treatment costs and slow MDR-TB transmission.We developed a dynamic transmission model of TB and drug resistance matched to the epidemiology and costs in FSU prisons. We evaluated eight strategies for TB screening and diagnosis involving, alone or in combination, self-referral, symptom screening, mass miniature radiography (MMR), and sputum PCR with probes for rifampin resistance (Xpert MTB/RIF). Over a 10-y horizon, we projected costs, quality-adjusted life years (QALYs), and TB and MDR-TB prevalence. Using sputum PCR as an annual primary screening tool among the general prison population most effectively reduced overall TB prevalence (from 2.78% to 2.31%) and MDR-TB prevalence (from 0.74% to 0.63%), and cost US$543/QALY for additional QALYs gained compared to MMR screening with sputum PCR reserved for rapid detection of MDR-TB. Adding sputum PCR to the currently used strategy of annual MMR screening was cost-saving over 10 y compared to MMR screening alone, but produced only a modest reduction in MDR-TB prevalence (from 0.74% to 0.69%) and had minimal effect on overall TB prevalence (from 2.78% to 2.74%). Strategies based on symptom screening alone were less effective and more expensive than MMR-based strategies. Study limitations included scarce primary TB time-series data in FSU prisons and uncertainties regarding screening test characteristics.In prisons of the FSU, annual screening of the general inmate population with sputum PCR most effectively reduces TB and MDR-TB prevalence, doing so cost-effectively. If this approach is not feasible, the current strategy of annual MMR is both more effective and less expensive than strategies using self-referral or symptom screening alone, and the addition of sputum PCR for rapid MDR-TB detection may be cost-saving over time. Please see later in the article for the Editors' Summary.",2012-01-10107,23209384,PLoS Med,Daniel E Winetsky,2012,9 / 11,e1001348,No,23209384,"Daniel E Winetsky; Diana M Negoescu; Emilia H Demarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern europe: a cost-effectiveness analysis, PLoS Med, ; 9(11):1549-1676; e1001348",QALY,Not Stated,Not Stated,Not Stated,Sputum polymerase chain reaction (PCR) screening vs. Mass miniature radiography (MMR) with PCR detection of multidrug resistant-tuberculosis (MDR-TB),Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,1258,United States,2009,1517.61
10528,Analysis of media campaign promoting smoking cessation suggests it was cost-effective in prompting quit attempts,"The American Legacy Foundation's national EX? campaign, which ran on radio and television in 2008, was designed to promote smoking cessation among adult smokers. The incremental societal cost of EX, in 2009 dollars, was $166?million. Data from eight designated media market areas studied indicate that in a hypothetical nationwide cohort of 2,012,000 adult smokers ages 18-49, EX resulted in 52,979 additional quit attempts and 4,238 additional quits and saved 4,450 quality-adjusted life-years. Incremental cost-utility estimates comparing EX to the status quo-that is, the situation that would have existed in the eight markets with no campaign and no change in cessation behavior-ranged from a cost of $37,355 to $81,301 per quality-adjusted life-year, which suggests that the campaign was cost-effective. These findings bolster previous evidence that national mass media campaigns for smoking cessation can lower smoking prevalence in a cost-effective manner, among both adults and young adults ages 18-24 who are smokers.",2012-01-10114,23213155,Health Aff (Millwood),Andrea C Villanti,2012,31 / 12,2708-16,No,23213155,"Andrea C Villanti; Laurel E Curry; Amanda Richardson; Donna M Vallone; David R Holtgrave; Analysis of media campaign promoting smoking cessation suggests it was cost-effective in prompting quit attempts, Health Aff (Millwood), ; 31(12):0278-2715; 2708-16",QALY,Not Stated,Not Stated,Not Stated,Media campaign promoting smoking cessation vs. Status-quo,Not Stated,49 Years,18 Years,"Female, Male",Full,Lifetime,3.00,Not Stated,37355,United States,2009,45063.95
10529,Analysis of media campaign promoting smoking cessation suggests it was cost-effective in prompting quit attempts,"The American Legacy Foundation's national EX? campaign, which ran on radio and television in 2008, was designed to promote smoking cessation among adult smokers. The incremental societal cost of EX, in 2009 dollars, was $166?million. Data from eight designated media market areas studied indicate that in a hypothetical nationwide cohort of 2,012,000 adult smokers ages 18-49, EX resulted in 52,979 additional quit attempts and 4,238 additional quits and saved 4,450 quality-adjusted life-years. Incremental cost-utility estimates comparing EX to the status quo-that is, the situation that would have existed in the eight markets with no campaign and no change in cessation behavior-ranged from a cost of $37,355 to $81,301 per quality-adjusted life-year, which suggests that the campaign was cost-effective. These findings bolster previous evidence that national mass media campaigns for smoking cessation can lower smoking prevalence in a cost-effective manner, among both adults and young adults ages 18-24 who are smokers.",2012-01-10114,23213155,Health Aff (Millwood),Andrea C Villanti,2012,31 / 12,2708-16,No,23213155,"Andrea C Villanti; Laurel E Curry; Amanda Richardson; Donna M Vallone; David R Holtgrave; Analysis of media campaign promoting smoking cessation suggests it was cost-effective in prompting quit attempts, Health Aff (Millwood), ; 31(12):0278-2715; 2708-16",QALY,Not Stated,Not Stated,Not Stated,Media campaign promoting smoking cessation vs. Status-quo,Not Stated,24 Years,18 Years,"Female, Male",Full,Lifetime,3.00,Not Stated,44427,United States,2009,53595.4
10530,Economic evaluation of a task-shifting intervention for common mental disorders in India,"To carry out an economic evaluation of a task-shifting intervention for the treatment of depressive and anxiety disorders in primary-care settings in Goa, India.Cost-utility and cost-effectiveness analyses based on generalized linear models were performed within a trial set in 24 public and private primary-care facilities. Subjects were randomly assigned to an intervention or a control arm. Eligible subjects in the intervention arm were given psycho-education, case management, interpersonal psychotherapy and/or antidepressants by lay health workers. Subjects in the control arm were treated by physicians. The use of health-care resources, the disability of each subject and degree of psychiatric morbidity, as measured by the Revised Clinical Interview Schedule, were determined at 2, 6 and 12 months.Complete data, from all three follow-ups, were collected from 1243 (75.4%) and 938 (81.7%) of the subjects enrolled in the study facilities from the public and private sectors, respectively. Within the public facilities, subjects in the intervention arm showed greater improvement in all the health outcomes investigated than those in the control arm. Time costs were also significantly lower in the intervention arm than in the control arm, whereas health system costs in the two arms were similar. Within the private facilities, however, the effectiveness and costs recorded in the two arms were similar.Within public primary-care facilities in Goa, the use of lay health workers in the care of subjects with common mental disorders was not only cost-effective but also cost-saving.",2012-01-10135,23226893,Bull World Health Organ,Christine Buttorff,2012,90 / 11,813-21,No,23226893,"Christine Buttorff; Rebecca S Hock; Helen A Weiss; Smita Naik; Ricardo Araya; Betty R Kirkwood; Daniel Chisholm; Vikram Patel; Economic evaluation of a task-shifting intervention for common mental disorders in India, Bull World Health Organ, Nov/1/2012; 90(11):0042-9686; 813-21",QALY,Not Stated,Not Stated,Not Stated,"Collaborative stepped care including psycho-education, case management, interpersonal psychotherapy and/or antidepressants by lay health workers vs. Enhanced usual care by physicians",Not Stated,Not Stated,18 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,-2300,United States,2009,-2774.65
10531,Economic evaluation of a task-shifting intervention for common mental disorders in India,"To carry out an economic evaluation of a task-shifting intervention for the treatment of depressive and anxiety disorders in primary-care settings in Goa, India.Cost-utility and cost-effectiveness analyses based on generalized linear models were performed within a trial set in 24 public and private primary-care facilities. Subjects were randomly assigned to an intervention or a control arm. Eligible subjects in the intervention arm were given psycho-education, case management, interpersonal psychotherapy and/or antidepressants by lay health workers. Subjects in the control arm were treated by physicians. The use of health-care resources, the disability of each subject and degree of psychiatric morbidity, as measured by the Revised Clinical Interview Schedule, were determined at 2, 6 and 12 months.Complete data, from all three follow-ups, were collected from 1243 (75.4%) and 938 (81.7%) of the subjects enrolled in the study facilities from the public and private sectors, respectively. Within the public facilities, subjects in the intervention arm showed greater improvement in all the health outcomes investigated than those in the control arm. Time costs were also significantly lower in the intervention arm than in the control arm, whereas health system costs in the two arms were similar. Within the private facilities, however, the effectiveness and costs recorded in the two arms were similar.Within public primary-care facilities in Goa, the use of lay health workers in the care of subjects with common mental disorders was not only cost-effective but also cost-saving.",2012-01-10135,23226893,Bull World Health Organ,Christine Buttorff,2012,90 / 11,813-21,No,23226893,"Christine Buttorff; Rebecca S Hock; Helen A Weiss; Smita Naik; Ricardo Araya; Betty R Kirkwood; Daniel Chisholm; Vikram Patel; Economic evaluation of a task-shifting intervention for common mental disorders in India, Bull World Health Organ, Nov/1/2012; 90(11):0042-9686; 813-21",QALY,Not Stated,Not Stated,Not Stated,"Collaborative stepped care including psycho-education, case management, interpersonal psychotherapy and/or antidepressants by lay health workers vs. Enhanced usual care by physicians",Not Stated,Not Stated,18 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,25,United States,2009,30.16
10532,Treatment of advanced or recurrent cervical cancer with Cisplatin or Cisplatin containing regimens: a cost effective analysis,"Trials have demonstrated improvements in survival with adding paclitaxel (P) or topotecan (T) to cisplatin (C) for the treatment of advanced cervical cancer. We sought to evaluate the cost effectiveness of these regimens.A decision model was developed based on Gynecologic Oncology Group (GOG) protocols 169 and 179. Arm 1 is 6 cycles of cisplatin. Arm 2 is 6 cycles of CP while arm 3 is 6 cycles of CT. Parameters include overall survival (OS), cost and complications. Sensitivity analyses were performed.The incremental cost-effectiveness ratio (ICER) for C versus CP is $13,654/quality-adjusted life-year (QALY) gained. For CT compared to C, the ICER is $152,327/QALY. When compared simultaneously, CT is dominated. At a willingness to pay (WTP) threshold of $50,000/QALY, C is the preferred option but CP is acceptable. Sensitivity analyses suggest that CT would become the preferred option if it was to improve OS to 24 months (compared to 9.4 months).In this model, CP is an acceptable alternative to cisplatin for the treatment of these patients with an increase in cost of only $13,654/QALY. The addition of topotecan did not increase survival enough to justify the increased cost.",2012-01-10151,23236342,J Cancer,John P Geisler,2012,3 /,454-8,No,23236342,"John P Geisler; Jayanth Swathirajan; Katherine L Wood; Kelly J Manahan; Treatment of advanced or recurrent cervical cancer with Cisplatin or Cisplatin containing regimens: a cost effective analysis, J Cancer, ; 3():1837-9664; 454-8",QALY,Not Stated,Not Stated,Not Stated,Cisplatain (50 mg per sq meter for 21 days) vs. Cisplatin (50 mg per sq meter) and paclitaxel (135 mg per sq meter) for 21 days,Not Stated,Not Stated,Not Stated,Female,Full,Not Stated / None,Not Stated,Not Stated,13654,United States,2011,15710.06
10533,Treatment of advanced or recurrent cervical cancer with Cisplatin or Cisplatin containing regimens: a cost effective analysis,"Trials have demonstrated improvements in survival with adding paclitaxel (P) or topotecan (T) to cisplatin (C) for the treatment of advanced cervical cancer. We sought to evaluate the cost effectiveness of these regimens.A decision model was developed based on Gynecologic Oncology Group (GOG) protocols 169 and 179. Arm 1 is 6 cycles of cisplatin. Arm 2 is 6 cycles of CP while arm 3 is 6 cycles of CT. Parameters include overall survival (OS), cost and complications. Sensitivity analyses were performed.The incremental cost-effectiveness ratio (ICER) for C versus CP is $13,654/quality-adjusted life-year (QALY) gained. For CT compared to C, the ICER is $152,327/QALY. When compared simultaneously, CT is dominated. At a willingness to pay (WTP) threshold of $50,000/QALY, C is the preferred option but CP is acceptable. Sensitivity analyses suggest that CT would become the preferred option if it was to improve OS to 24 months (compared to 9.4 months).In this model, CP is an acceptable alternative to cisplatin for the treatment of these patients with an increase in cost of only $13,654/QALY. The addition of topotecan did not increase survival enough to justify the increased cost.",2012-01-10151,23236342,J Cancer,John P Geisler,2012,3 /,454-8,No,23236342,"John P Geisler; Jayanth Swathirajan; Katherine L Wood; Kelly J Manahan; Treatment of advanced or recurrent cervical cancer with Cisplatin or Cisplatin containing regimens: a cost effective analysis, J Cancer, ; 3():1837-9664; 454-8",QALY,Not Stated,Not Stated,Not Stated,Cisplatain (50 mg per sq meter for 21 days) vs. Cisplatin (50 mg per sq meter for 21 days) and topotecan (0.75 mg per sq meter for 21 days),Not Stated,Not Stated,Not Stated,Female,Full,Not Stated / None,Not Stated,Not Stated,152327,United States,2011,175264.86
10534,"How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies","Because of rising drug expenditures, cost considerations have become essential, necessitating the requirement for cost-effectiveness analyses for managed care organizations (MCOs). The study objective is to examine the impact of various drug-cost components, in addition to wholesale acquisition cost (WAC), on the cost-effectiveness of osteoporosis therapies.A Markov model of osteoporosis was used to exemplify different drug cost scenarios.We examined the effect of varying rebates for oral bisphosphonates--risedronate and ibandronate--as well as considering the impact of varying copayments and administration costs for intravenous zoledronate. The population modeled was 1,000 American women, > or = 50 years with osteoporosis. Patients were followed for 1 year to reflect an annual budget review of formularies by MCOs. The cost of therapy was based on an adjusted WAC, and is referred to as net drug cost. The total annual cost incurred by an MCO for each drug regimen was calculated using the net drug cost and fracture cost. We estimated cost on a quality adjusted life year (QALY) basis.When considering different rebates, results for risedronate versus ibandronate vary from cost-savings (i.e., costs less and more effective) to approximately $70,000 per QALY. With no risedronate rebate, an ibandronate rebate of approximately 65% is required before cost per QALY surpasses $50,000. With rebates greater than 25% for risedronate, irrespective of ibandronate rebates, results become cost-saving. Results also showed the magnitude of cost savings to the MCO varied by as much as 65% when considering no administration cost and the highest coinsurance rate for zoledronate.Our study showed that cost-effectiveness varies considerably when factors in addition to the WAC are considered. This paper provides recommendations for pharmaceutical manufacturers and MCOs when developing and interpreting such analyses.",2012-01-10154,23236717,Manag Care,Nicole C Ferko,2012,21 / 11,44-52,No,23236717,"Nicole C Ferko; Natalie Borisova; Parisa Airia; Daniel T Grima; Melissa F Thompson; How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies, Manag Care, ; 21(11):1062-3388; 44-52",QALY,Not Stated,Not Stated,Not Stated,Risedronate (oral bisphosphonate) vs. Ibandronate (oral bisphosphonate),Not Stated,Not Stated,50 Years,Female,Full,1 Year,Not Stated,Not Stated,Not Stated,United States,2009,Not Stated
10535,Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent beta-thalassemia patients,"BACKGROUND: Deferasirox (DFX) is a novel iron chelator that has been shown to have similar efficacy and safety compared with deferoxamine (DFO) in patients with beta-thalassemia. The aim of this study was to determine the cost utility of DFX versus DFO in beta-thalassemia major patients from Iran''s society perspective. STUDY DESIGN AND METHODS: A Markov model has been developed to determine lifetime cost and quality-adjusted life-years (QALYs) of patients. To estimate the annual cost of each method, a cross-sectional study was conducted among two groups of patients who received DFO and DFX (n = 100 and n = 45, respectively). Also a time trade-off method was used to estimate the utility of two strategies. Finally a one-way and probabilistic sensitivity analysis was conducted to examine the strength of the results. RESULTS: Our base-case analysis showed that estimated total lifetime costs per patient for DFX and DFO were 47,029 international dollar ($Int) and $Int143,522, respectively, while the estimated total discounted QALYs per person were 12.28 and 7.76, respectively. Calculated incremental cost-effectiveness ratio showed that DSX is a dominant therapy and its estimated lifetime net monetary benefit was $Int273,528. CONCLUSION: We conclude that the use of DFX instead of DFO represents a cost-effective use of resources for treatment of iron overload in patients with beta-thalassemia from Iran''s society perspective.",2012-01-10162,23241074,Transfusion,Ali Keshtkaran,2013,53 / 8,,No,23241074,"Ali Keshtkaran; Mehdi Javanbakht; Sedigheh Salavati; Atefeh Mashayekhi; Mehran Karimi; Bijan Nuri; Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent beta-thalassemia patients, Transfusion, ; 53(8):0041-1132",QALY,Not Stated,Not Stated,Not Stated,Oral deferasirox once daily vs. Deferoxamine (5 days per week),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,3.00,Not Stated,United States,2010,Not Stated
10536,Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer,"Fine-needle aspiration biopsy (FNAB) is a safe and inexpensive diagnostic procedure for evaluating thyroid nodules.Up to 25% of the results from an FNAB, however, may not be diagnostic or may be indeterminate, leading to a subsequent diagnostic thyroid surgery. A new molecularly based diagnostic test could potentially reduce indeterminate cytological results and, with high accuracy, provide a definitive diagnosis for cancer in thyroid nodules. The aim of the study was to estimate the cost-effectiveness of utilizing a molecular diagnostic (DX) test as an adjunct to FNAB, compared with NoDX, to improve the preoperative diagnosis of thyroid nodules.We constructed a patient-level simulation model to estimate the clinical and economic outcomes of using a DX test compared with current practice (NoDX) for the diagnosis of thyroid nodules. By using a cost-effectiveness framework, we measured incremental clinical benefits in terms of quality-adjusted life-years and incremental costs over a 10-year time horizon.Assuming 95% sensitivity and specificity of the Dx test when used as an adjunct to FNAB, the utilization of the DX test resulted in a gain of 0.046 quality-adjusted life-years (95% confidence interval 0.019-0.078) and a saving of $1087 (95% confidence interval $691-$1533) in direct costs per patient. If the cost of the Dx test is less than $1087 per test, we expect to save quality-adjusted life-years and reduce costs when it is utilized. Sensitivity of the DX test, compared with specificity, had a larger influence on the overall outcomes.",2012-01-10167,23244801,Value Health,Mehdi Najafzadeh,2013,15 / 8,1005-13,Yes,23244801,"Mehdi Najafzadeh; Carlo A Marra; Larry D Lynd; Sam M Wiseman; Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer, Value Health, ; 15(8):1098-3015; 1005-13",QALY,Not Stated,Not Stated,Not Stated,Fine-needle aspiration biopsy (FNAB) with a new molecular diagnostic test as an addition (DX) vs. FNAB in combination with the the Bethesta System for reporting thyroid cytopathology guidelines,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-27000,United States,2011,-31065.74
10537,"A Multigene Prognostic Assay for Selection of Adjuvant Chemotherapy in Patients with T3, Stage II Colon Cancer: Impact on Quality-Adjusted Life Expectancy and Costs","Uncertainty exists regarding appropriate and affordable use of adjuvant chemotherapy in stage II colon cancer (T3, proficient DNA mismatch repair). This study aimed to estimate the effectiveness and costs from a US societal perspective of a multigene recurrence score (RS) assay for patients recently diagnosed with stage II colon cancer (T3, proficient DNA mismatch repair) eligible for adjuvant chemotherapy.RS was compared with guideline-recommended clinicopathological factors (tumor stage, lymph nodes examined, tumor grade, and lymphovascular invasion) by using a state-transition (Markov) lifetime model. Data were obtained from published literature, a randomized controlled trial (QUick And Simple And Reliable) of adjuvant chemotherapy, and rates of chemotherapy use from the National Cooperative Cancer Network Colon/Rectum Cancer Outcomes study. Life-years, quality-adjusted life expectancy, and lifetime costs were examined.The RS is projected to reduce adjuvant chemotherapy use by 17% compared with current treatment patterns and to increase quality-adjusted life expectancy by an average of 0.035 years. Direct medical costs are expected to decrease by an average of $2971 per patient. The assay was cost saving for all subgroups of patients stratified by clinicopathologic factors. The most influential variables affecting treatment decisions were projected years of life remaining, recurrence score, and patients' disutilities associated with adjuvant chemotherapy.Use of the multigene RS to assess recurrence risk after surgery in stage II colon cancer (T3, proficient DNA mismatch repair) may reduce the use of adjuvant chemotherapy without decreasing quality-adjusted life expectancy and be cost saving from a societal perspective. These findings need to be validated in additional cohorts, including studies of clinical practice as assay use diffuses into nonacademic settings.",2012-01-10168,23244802,Value Health,John Hornberger,2013,15 / 8,1014-21,Yes,23244802,"John Hornberger; Gary H Lyman; Rebecca Chien; Neal J Meropol; A Multigene Prognostic Assay for Selection of Adjuvant Chemotherapy in Patients with T3, Stage II Colon Cancer: Impact on Quality-Adjusted Life Expectancy and Costs, Value Health, ; 15(8):1098-3015; 1014-21",QALY,Not Stated,Not Stated,Not Stated,"Multigene recurrence score (RS) assay for patients recently diagnosed with stage II colon cancer eligible for adjuvant chemotherapy vs. Examination of guideline-recommended clinicopathological factors ((tumor stage, lymph nodes examined, tumor grade and lymphovascular invasion)",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,-84885.71,United States,2011,-97668.06
10538,QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis,"ABSTRACT:The tuberculin skin test (TST) has limitations for latent tuberculosis infection (LTBI) diagnosis in low-prevalence settings. Previously, all TST-positive individuals referred from the community to Baltimore City Health Department (BCHD) were offered LTBI treatment, after active TB was excluded. In 2010, BCHD introduced adjunctive QuantiFERON-TB Gold In-Tube (QFT-GIT) testing for TST-positive referrals. We evaluated costs and cost-effectiveness of this new diagnostic algorithm.A decision-analysis model compared the strategy of treating all TST-positive referrals versus only those with positive results on adjunctive QFT-GIT testing. Costs were collected at BCHD, and Incremental Cost-Effectiveness Ratios (ICERs) were utilized to report on cost-effectiveness.QFT-GIT testing at BCHD cost $43.51 per test. Implementation of QFT-GIT testing was associated with an ICER of $1,202 per quality-adjusted life-year gained and was considered highly cost-effective. In sensitivity analysis, the QFT-GIT strategy became cost-saving if QFT-GIT sensitivity increased above 92% or if less than 3.5% of individuals with LTBI progress to active TB disease.LTBI screening with TST in low-prevalence settings may lead to overtreatment and increased expenditures. In this public health clinic, additional QFT-GIT testing of individuals referred for a positive TST was cost-effective.",2012-01-10184,23253780,BMC Infect Dis,Maunank Shah,2012,12 /,360,No,23253780,"Maunank Shah; Kathryn Miele; Howard Choi; Danielle Dipietro; Maria Martins-Evora; Vincent Marsiglia; Susan Dorman; QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis, BMC Infect Dis, ; 12():1471-2334; 360",QALY,Not Stated,Not Stated,Not Stated,"Additional interferon-gamma release assays (QuantiFERON-TB Gold In-Tube testing) for all referred individuals including tuberculin skin test (TST) positive individuals along with routine testings such as chest x-ray, liver chemistries followed by treatment for all TST-positive referrals vs. Chest x-ray, liver chemistries on tuberculin skin test positive individuals followed by treatment for all TST-positive referrals",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,1012,United States,2012,1140.78
10539,Cost-effectiveness of a health-social partnership transitional program for post-discharge medical patients,"ABSTRACT:Readmissions are costly and have implications for quality of care. Studies have been reported to support effects of transitional care programs in reducing hospital readmissions and enhancing clinical outcomes. However, there is a paucity of studies executing full economic evaluation to assess the cost-effectiveness of these transitional care programs. This study is therefore launched to fill this knowledge gap.Cost-effectiveness analysis was conducted alongside a randomized controlled trial that examined the effects of a Health-Social Transitional Care Management Program (HSTCMP) for medical patients discharged from an acute regional hospital in Hong Kong. The cost and health outcomes were compared between the patients receiving the HSTCMP and usual care. The total costs comprised the pre-program, program, and healthcare utilization costs. Quality of life was measured with SF-36 and transformed to utility values between 0 and 1.The readmission rates within 28 (control 10.2%, study 4.0%) and 84 days (control 19.4%, study 8.1%) were significantly higher in the control group. Utility values showed no difference between the control and study groups at baseline (p?=?0.308). Utility values for the study group were significantly higher than in the control group at 28 (p?<?0.001) and 84 days (p?=?0.002). The study group also had a significantly higher QALYs gain (p?<?0.001) over time at 28 and 84 days when compared with the control group. The intervention had an 89% chance of being cost-effective at the threshold of ?20000/QALY.Previous studies on transitional care focused mainly on clinical outcomes and not too many included cost as an outcome measure. Studies examining the cost-effectiveness of the post-discharge support services are scanty. This study is the first to examine the cost-effectiveness of a transitional care program that used nurse-led services participated by volunteers. Results have shown that a health-social partnership transitional care program is cost-effective in reducing healthcare costs and attaining QALY gains. Economic evaluation helps to inform funders and guide decisions for the effective use of competing healthcare resources.",2012-01-10190,23259498,BMC Health Serv Res,Frances Kam Yuet Wong,2012,12 /,479,Yes,23259498,"Frances Kam Yuet Wong; June Chau; Ching So; Stanley Ku Fu Tam; Sarah McGhee; Cost-effectiveness of a health-social partnership transitional program for post-discharge medical patients, BMC Health Serv Res, ; 12():1472-6963; 479",QALY,Not Stated,Not Stated,Not Stated,"Usual care and a health-social partnership transitional care management program for 28 days (weekly planned events delivered by the nurse case manager (NCM) and trained volunteers (TV), guided by protocols and structured documentations) vs. Usual care for 28 days",Not Stated,Not Stated,61 Years,"Female, Male",Full,12 Weeks,Not Stated,Not Stated,-140000,Hong Kong,2010,-21389.33
10540,Cost-effectiveness of a health-social partnership transitional program for post-discharge medical patients,"ABSTRACT:Readmissions are costly and have implications for quality of care. Studies have been reported to support effects of transitional care programs in reducing hospital readmissions and enhancing clinical outcomes. However, there is a paucity of studies executing full economic evaluation to assess the cost-effectiveness of these transitional care programs. This study is therefore launched to fill this knowledge gap.Cost-effectiveness analysis was conducted alongside a randomized controlled trial that examined the effects of a Health-Social Transitional Care Management Program (HSTCMP) for medical patients discharged from an acute regional hospital in Hong Kong. The cost and health outcomes were compared between the patients receiving the HSTCMP and usual care. The total costs comprised the pre-program, program, and healthcare utilization costs. Quality of life was measured with SF-36 and transformed to utility values between 0 and 1.The readmission rates within 28 (control 10.2%, study 4.0%) and 84 days (control 19.4%, study 8.1%) were significantly higher in the control group. Utility values showed no difference between the control and study groups at baseline (p?=?0.308). Utility values for the study group were significantly higher than in the control group at 28 (p?<?0.001) and 84 days (p?=?0.002). The study group also had a significantly higher QALYs gain (p?<?0.001) over time at 28 and 84 days when compared with the control group. The intervention had an 89% chance of being cost-effective at the threshold of ?20000/QALY.Previous studies on transitional care focused mainly on clinical outcomes and not too many included cost as an outcome measure. Studies examining the cost-effectiveness of the post-discharge support services are scanty. This study is the first to examine the cost-effectiveness of a transitional care program that used nurse-led services participated by volunteers. Results have shown that a health-social partnership transitional care program is cost-effective in reducing healthcare costs and attaining QALY gains. Economic evaluation helps to inform funders and guide decisions for the effective use of competing healthcare resources.",2012-01-10190,23259498,BMC Health Serv Res,Frances Kam Yuet Wong,2012,12 /,479,Yes,23259498,"Frances Kam Yuet Wong; June Chau; Ching So; Stanley Ku Fu Tam; Sarah McGhee; Cost-effectiveness of a health-social partnership transitional program for post-discharge medical patients, BMC Health Serv Res, ; 12():1472-6963; 479",QALY,Not Stated,Not Stated,Not Stated,"Usual care and a health-social partnership transitional care management program for 84 days (weekly planned events delivered by the nurse case manager (NCM) and trained volunteers (TV), guided by protocols and structured documentations) vs. Usual care for 84 days",Not Stated,Not Stated,61 Years,"Female, Male",Full,12 Weeks,Not Stated,Not Stated,-197111.13,Hong Kong,2010,-30114.82
10541,Self-management support for moderate-to-severe chronic obstructive pulmonary disease: a pilot randomised controlled trial,"Better self management could improve quality of life (QoL) and reduce hospital admissions in chronic obstructive pulmonary disease (COPD), but the best way to promote it remains unclear.To explore the feasibility, effectiveness and cost effectiveness of a novel, layperson-led, theoretically driven COPD self-management support programme.Pilot randomised controlled trial in one UK primary care trust area.Patients with moderate to severe COPD were identified through primary care and randomised 2:1 to the 7-week-long, group intervention or usual care. Outcomes at baseline, 2, and 6 months included self-reported health, St George's Respiratory Questionnaire (SGRQ), EuroQol, and exercise.Forty-four per cent responded to GP invitation, 116 were randomised: mean (standard deviation [SD]) age 69.5 (9.8) years, 46% male, 78% had unscheduled COPD care in the previous year. Forty per cent of intervention patients completed the course; 35% attended no sessions; and 78% participants completed the 6-month follow-up questionnaire. Results suggest that the intervention may increase both QoL (mean EQ-5D change 0.12 (95% confidence interval [CI] = -0.02 to 0.26) higher, intervention versus control) and exercise levels, but not SGRQ score. Economic analyses suggested that with thresholds of ?20 000 per quality-adjusted life-year gained, the intervention is likely to be cost-effective.This intervention has good potential to meet the UK National Institute for Health and Clinical Excellence criteria for cost effectiveness, and further research is warranted. However, to make a substantial impact on COPD self-management, it will also be necessary to explore other ways to enable patients to access self-management education.",2012-01-10197,23265228,Br J Gen Pract,Stephanie J C Taylor,2012,62 / 603,687-95,No,23265228,"Stephanie J C Taylor; Ratna Sohanpal; Stephen A Bremner; Angela Devine; David McDaid; Jos?-Luis Fern?ndez; Chris J Griffiths; Sandra Eldridge; Self-management support for moderate-to-severe chronic obstructive pulmonary disease: a pilot randomised controlled trial, Br J Gen Pract, ; 62(603):0960-1643; 687-95",QALY,Not Stated,Not Stated,Not Stated,Better Living with Longterm Airways disease (BELLA)- 2 trained tutors delivering a structured manualised 3 hour session once a week for 7 weeks addressing five core self-management skills vs. Usual care,Not Stated,Not Stated,36 Years,"Female, Male",Full,6 Months,Not Stated,Not Stated,11710,United Kingdom,2010,21456.49
10542,TIPP and Lichtenstein modalities for inguinal hernia repair: a cost minimisation analysis alongside a randomised trial,"The transinguinal preperitoneal (TIPP) technique using a soft mesh with a memory ring was developed recently for inguinal hernia repair. To compare TIPP with the Lichtenstein method, a randomised trial was conducted (ISRCTN93798494). The aim of this study was to perform an economic evaluation of the TIPP modality compared to the Lichtenstein modality from both a hospital and societal perspective alongside the clinical trial. The TULIP study was a double-blind randomised clinical trial comparing two techniques for inguinal hernia repair (TIPP and Lichtenstein). Correct generation of the allocation sequence, allocation concealment, blinding, and follow-up were used/applied according to the recommendations of the Cochrane Handbook. Next to the cost drivers, the short-form-36 health survey (SF-36) data from the TULIP trial was used to determine utility. The SF-36 data from the TULIP trial were revised using the SF-6D algorithm according to Brazier. Two scenarios-a hospital and a societal perspective-were presented. If the analyses showed no difference in effects (on the SF-6D) the cost effectiveness decision rule to cost minimisation was altered. No significant difference in SF-6D utility between both modalities was found (mean difference: 0.888, 95% CI -1.02 to 1.23); consequently, the economic decision rule became cost minimisation. For the hospital perspective no significant differences in costs were found (mean difference: euro -13, 95% CI euro -130 to euro 104). However, when including productivity gains in the analysis, significant differences (P = 0.037) in costs favouring the TIPP modality (mean saving: euro 1,472, 95% CI euro 463- euro 2,714) were found. The results show that TIPP is a cost-saving inguinal hernia repair technique compared to the Lichtenstein modality against equal effectiveness expressed as quality adjusted life week at 1 year given a societal perspective. In the trial, TIPP patients showed on average a quicker recovery of 6.5 days compared to Lichtenstein patients.",2012-01-10204,23271350,Eur J Health Econ,G G Koning,2013,14 / 6,,Yes,23271350,"G G Koning; E M M Adang; P F M Stalmeier; F Keus; P W H E Vriens; C J H M van Laarhoven; TIPP and Lichtenstein modalities for inguinal hernia repair: a cost minimisation analysis alongside a randomised trial, Eur J Health Econ, ; 14(6):1618-7598",QALY,Netherlands,Not Stated,Not Stated,Transinguinal preperitoneal (TIPP) technique using a soft mesh with a memory ring vs. Lichtenstein technique,Not Stated,80 Years,18 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,-1322.48,Euro,2010,-2077.34
10543,Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation,"BACKGROUND: Positive screening results are often associated not only with target-disease-specific but also with non-target-disease-specific mortality. In general, this association is due to joint risk factors. Cost-effectiveness estimates based on decision-analytic models may be biased if this association is not reflected appropriately. OBJECTIVE: To develop a procedure for quantifying the degree of bias when an increase in non-target-disease-specific mortality is not considered. METHODS: We developed a family of parametric functions that generate hazard ratios (HRs) of non-target-disease-specific mortality between subjects screened positive and negative, with the HR of target-disease-specific mortality serving as the input variable. To demonstrate the efficacy of this procedure, we fitted a function within the context of coronary artery disease (CAD) risk screening, based on HRs related to different risk factors extracted from published studies. Estimates were embedded into a decision-analytic model, and the impact of ''modelling increased non-target-disease-specific mortality'' was assessed. RESULTS: In 55-year-old German men, based on a risk screening with 5% positively screened subjects, and a CAD risk ratio of 6 within the first year after screening, incremental quality-adjusted life-years were 19% higher and incremental costs were 8% lower if no adjustment was made. The effect varied depending on age, gender, the explanatory power of the screening test and other factors. CONCLUSION: Some bias can occur when an increase in non-target-disease-specific mortality is not considered when modelling the outcomes of screening tests.",2012-01-10209,23275043,Eur J Health Econ,Bjorn Stollenwerk,2013,14 / 6,,Yes,23275043,"Bjorn Stollenwerk; Afschin Gandjour; Markus Lungen; Uwe Siebert; Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation, Eur J Health Econ, ; 14(6):1618-7598",QALY,Germany,Not Stated,Not Stated,Screening for CAD risk vs. None,Not Stated,50 Years,50 Years,Male,Full,Lifetime,3.00,3.00,9518,Euro,2011,15239.52
10544,Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation,"BACKGROUND: Positive screening results are often associated not only with target-disease-specific but also with non-target-disease-specific mortality. In general, this association is due to joint risk factors. Cost-effectiveness estimates based on decision-analytic models may be biased if this association is not reflected appropriately. OBJECTIVE: To develop a procedure for quantifying the degree of bias when an increase in non-target-disease-specific mortality is not considered. METHODS: We developed a family of parametric functions that generate hazard ratios (HRs) of non-target-disease-specific mortality between subjects screened positive and negative, with the HR of target-disease-specific mortality serving as the input variable. To demonstrate the efficacy of this procedure, we fitted a function within the context of coronary artery disease (CAD) risk screening, based on HRs related to different risk factors extracted from published studies. Estimates were embedded into a decision-analytic model, and the impact of ''modelling increased non-target-disease-specific mortality'' was assessed. RESULTS: In 55-year-old German men, based on a risk screening with 5% positively screened subjects, and a CAD risk ratio of 6 within the first year after screening, incremental quality-adjusted life-years were 19% higher and incremental costs were 8% lower if no adjustment was made. The effect varied depending on age, gender, the explanatory power of the screening test and other factors. CONCLUSION: Some bias can occur when an increase in non-target-disease-specific mortality is not considered when modelling the outcomes of screening tests.",2012-01-10209,23275043,Eur J Health Econ,Bjorn Stollenwerk,2013,14 / 6,,Yes,23275043,"Bjorn Stollenwerk; Afschin Gandjour; Markus Lungen; Uwe Siebert; Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation, Eur J Health Econ, ; 14(6):1618-7598",QALY,Germany,Not Stated,Not Stated,Screening for CAD risk vs. None,Not Stated,50 Years,50 Years,Male,Full,Lifetime,3.00,3.00,10416,Euro,2011,16677.33
10545,Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer,"OBJECTIVES: Intensity-modulated radiation therapy (IMRT) has been established as the standard external-beam modality in treating low-risk prostate cancer. Stereotactic body radiotherapy (SBRT) is a novel approach involving high-dose radiotherapy in 5 fractions. This analysis compared their cost-effectiveness. METHODS: A Markov model was constructed to delineate the health states after treatment with IMRT and SBRT. Disease, treatment, and toxicity data were extracted from the literature. Costs included both robotic (R-SBRT) and nonrobotic (NR-SBRT) reimbursement. Deterministic and probabilistic sensitivity analyses (PSA) were performed over a wide range of potential parameters. RESULTS: The quality-adjusted life expectancy after IMRT was slightly higher than after SBRT, because we assumed worse toxicity after SBRT. However, the incremental cost-effectiveness ratios (ICER) for IMRT over R-SBRT and NR-SBRT were $285,000 and $591,100/quality-adjusted life year (QALY), respectively. On sensitivity analysis, SBRT was almost always the cost-effective therapy, in which the ICER for IMRT was generally over $100,000/QALY. Reimbursement for R-SBRT versus NR-SBRT significantly influenced its ICER. Treatment efficacy, rectal toxicity and impotence, and the potential for unforeseen SBRT late effects were the most critical parameters in the model; when including these uncertain parameters in a PSA, SBRT was still most likely to be cost-effective at a willingness to pay of $100,000/QALY. CONCLUSIONS: SBRT clearly contained more value than IMRT for external-beam treatment. Given the increasing prevalence of the disease and its superb convenience, intensive research should be performed on this novel modality, including the marginal benefit and cost of robotic treatment.",2012-01-10210,23275277,Am J Clin Oncol,David J Sher,2014,37 / 3,,No,23275277,"David J Sher; Ravi B Parikh; Shawnda Mays-Jackson; Rinaa S Punglia; Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer, Am J Clin Oncol, 2014 Jun; 37(3):1537-453X",QALY,Not Stated,Not Stated,Not Stated,Intensity-modulated radiation therapy (IMRT) vs. Robotic Stereotactic body radiotherapy (R-SBRT),Not Stated,Not Stated,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,285000,United States,2012,321267.69
10546,Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer,"OBJECTIVES: Intensity-modulated radiation therapy (IMRT) has been established as the standard external-beam modality in treating low-risk prostate cancer. Stereotactic body radiotherapy (SBRT) is a novel approach involving high-dose radiotherapy in 5 fractions. This analysis compared their cost-effectiveness. METHODS: A Markov model was constructed to delineate the health states after treatment with IMRT and SBRT. Disease, treatment, and toxicity data were extracted from the literature. Costs included both robotic (R-SBRT) and nonrobotic (NR-SBRT) reimbursement. Deterministic and probabilistic sensitivity analyses (PSA) were performed over a wide range of potential parameters. RESULTS: The quality-adjusted life expectancy after IMRT was slightly higher than after SBRT, because we assumed worse toxicity after SBRT. However, the incremental cost-effectiveness ratios (ICER) for IMRT over R-SBRT and NR-SBRT were $285,000 and $591,100/quality-adjusted life year (QALY), respectively. On sensitivity analysis, SBRT was almost always the cost-effective therapy, in which the ICER for IMRT was generally over $100,000/QALY. Reimbursement for R-SBRT versus NR-SBRT significantly influenced its ICER. Treatment efficacy, rectal toxicity and impotence, and the potential for unforeseen SBRT late effects were the most critical parameters in the model; when including these uncertain parameters in a PSA, SBRT was still most likely to be cost-effective at a willingness to pay of $100,000/QALY. CONCLUSIONS: SBRT clearly contained more value than IMRT for external-beam treatment. Given the increasing prevalence of the disease and its superb convenience, intensive research should be performed on this novel modality, including the marginal benefit and cost of robotic treatment.",2012-01-10210,23275277,Am J Clin Oncol,David J Sher,2014,37 / 3,,No,23275277,"David J Sher; Ravi B Parikh; Shawnda Mays-Jackson; Rinaa S Punglia; Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer, Am J Clin Oncol, 2014 Jun; 37(3):1537-453X",QALY,Not Stated,Not Stated,Not Stated,Intensity-modulated radiation therapy (IMRT) vs. Non-Robotic Stereotactic body radiotherapy (NR-SBRT),Not Stated,Not Stated,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,591100,United States,2012,666320.47
10547,Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma,"In the U.K. Medical Research Council Myeloma IX trial (mmix), zoledronic acid 4 mg once every 3-4 weeks, compared with clodronate 1600 mg daily, reduced the incidence of skeletal related events (sres), increased progression-free survival (pfs), and prolonged overall survival (os) in 1970 patients with newly-diagnosed multiple myeloma. The incidence of confirmed osteonecrosis of the jaw was higher with zoledronic acid than with clodronate. The objective of the present study was to evaluate, based on the findings in mmix, the cost-effectiveness of zoledronic acid compared with clodronate in patients with newly-diagnosed multiple myeloma.An economic model was used to project pfs, os, the incidence of sres and adverse events, and expected lifetime health care costs for patients with newly diagnosed multiple myeloma who are alternatively assumed to receive zoledronic acid or clodronate. The incremental cost-effectiveness ratio (icer) of zoledronic acid compared with clodronate was calculated as the ratio of the difference in cost to the difference in quality-adjusted life years (qalys). Model inputs were based on results of mmix and published sources. Results were generated under different assumptions regarding the beneficial effects of zoledronic acid on os beyond 5 years after treatment initiation.Assuming lifetime treatment effects of zoledronic acid, treatment with zoledronic acid (compared with clodronate) increased qalys by 0.27 at an additional cost of CA$13,407, yielding an icer of CA$49,829 per qaly gained. If the threshold icer is CA$100,000 per qaly, the estimated probability that zoledronic acid is cost-effective is 80%. Assuming that the benefits of zoledronic acid on pfs and os diminish over 5 years beginning at the end of year 5, the icer is CAN$63,027 per qaly gained. If the benefits of zoledronic acid on pfs and os are assumed to persist for 5 years only, the icer is CAN$76,948 per qaly gained.Compared with clodronate, zoledronic acid represents a cost-effective treatment alternative in patients with multiple myeloma.",2012-01-10220,23300363,Curr Oncol,T E Delea,2012,19 / 6,e392-403,No,23300363,"T E Delea; K El Ouagari; J Rotter; A Wang; S Kaura; G J Morgan; Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma, Curr Oncol, ; 19(6):1198-0052; e392-403",QALY,Not Stated,Not Stated,Not Stated,Bisphosphonate therapy with zoledronic acid (4 mg every 3-4 weeks) vs. Bisphosphonate therapy with clodronate (1600 mg daily),Not Stated,Not Stated,19 Years,"Female, Male",Full,20 Years,5.00,5.00,49829,Canada,2010,57450.55
10548,Antenatal corticosteroids for late-preterm infants: a decision-analytic and economic analysis,"Objectives. Antenatal corticosteroids (ACS) are not routinely administered to patients at risk for delivery between 34 and 36 6/7 weeks. Our objective was to determine whether ACS are cost-effective for late-preterm infants at risk for imminent preterm delivery. We hypothesized that the preferred strategy <36 weeks would include ACS while the preferred strategy =36 weeks would not. Methods. We performed decision-analytic and cost-effectiveness analyses to determine whether ACS was cost-effective at 34, 35, and 36 weeks. We conducted a literature review to determine probability, utility, and cost estimates absent of patient-level data. Base-case cost-effectiveness analysis, univariable sensitivity analysis, and Monte Carlo simulation were performed. A threshold of $100,000/QALY was considered cost-effective. Results. The incremental cost-effectiveness ratio favored the administration of a full course of ACS at 34, 35, and 36 weeks ($62,888.25/QALY, $64,425.67/QALY, and $64,793.71/QALY, resp.). A partial course of ACS was not cost-effective. While ACS was the consistently dominant strategy for acute respiratory outcomes, all models were sensitive to changes in variables associated with chronic respiratory disease. Conclusions. Our findings suggest that the administration of ACS to patients at risk of imminent delivery 34-36 weeks could significantly reduce the cost and acute morbidity associated with late-preterm birth.",2012-01-10222,23326677,ISRN Obstet Gynecol,Jamie A Bastek,2012,2012 /,491595,No,23326677,"Jamie A Bastek; Holly Langmuir; Laxmi A Kondapalli; Emmanuelle Par?; Joanna E Adamczak; Sindhu K Srinivas; Antenatal corticosteroids for late-preterm infants: a decision-analytic and economic analysis, ISRN Obstet Gynecol, ; 2012():2090-4444; 491595",QALY,Not Stated,Not Stated,Not Stated,Antenatal corticosteroids (ACS) at 34 weeks vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,Not Stated,62888.25,United States,2011,72358.15
10549,Antenatal corticosteroids for late-preterm infants: a decision-analytic and economic analysis,"Objectives. Antenatal corticosteroids (ACS) are not routinely administered to patients at risk for delivery between 34 and 36 6/7 weeks. Our objective was to determine whether ACS are cost-effective for late-preterm infants at risk for imminent preterm delivery. We hypothesized that the preferred strategy <36 weeks would include ACS while the preferred strategy =36 weeks would not. Methods. We performed decision-analytic and cost-effectiveness analyses to determine whether ACS was cost-effective at 34, 35, and 36 weeks. We conducted a literature review to determine probability, utility, and cost estimates absent of patient-level data. Base-case cost-effectiveness analysis, univariable sensitivity analysis, and Monte Carlo simulation were performed. A threshold of $100,000/QALY was considered cost-effective. Results. The incremental cost-effectiveness ratio favored the administration of a full course of ACS at 34, 35, and 36 weeks ($62,888.25/QALY, $64,425.67/QALY, and $64,793.71/QALY, resp.). A partial course of ACS was not cost-effective. While ACS was the consistently dominant strategy for acute respiratory outcomes, all models were sensitive to changes in variables associated with chronic respiratory disease. Conclusions. Our findings suggest that the administration of ACS to patients at risk of imminent delivery 34-36 weeks could significantly reduce the cost and acute morbidity associated with late-preterm birth.",2012-01-10222,23326677,ISRN Obstet Gynecol,Jamie A Bastek,2012,2012 /,491595,No,23326677,"Jamie A Bastek; Holly Langmuir; Laxmi A Kondapalli; Emmanuelle Par?; Joanna E Adamczak; Sindhu K Srinivas; Antenatal corticosteroids for late-preterm infants: a decision-analytic and economic analysis, ISRN Obstet Gynecol, ; 2012():2090-4444; 491595",QALY,Not Stated,Not Stated,Not Stated,Antenatal corticosteroids (ACS) at 35 weeks vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,Not Stated,64425.67,United States,2011,74127.08
10550,Antenatal corticosteroids for late-preterm infants: a decision-analytic and economic analysis,"Objectives. Antenatal corticosteroids (ACS) are not routinely administered to patients at risk for delivery between 34 and 36 6/7 weeks. Our objective was to determine whether ACS are cost-effective for late-preterm infants at risk for imminent preterm delivery. We hypothesized that the preferred strategy <36 weeks would include ACS while the preferred strategy =36 weeks would not. Methods. We performed decision-analytic and cost-effectiveness analyses to determine whether ACS was cost-effective at 34, 35, and 36 weeks. We conducted a literature review to determine probability, utility, and cost estimates absent of patient-level data. Base-case cost-effectiveness analysis, univariable sensitivity analysis, and Monte Carlo simulation were performed. A threshold of $100,000/QALY was considered cost-effective. Results. The incremental cost-effectiveness ratio favored the administration of a full course of ACS at 34, 35, and 36 weeks ($62,888.25/QALY, $64,425.67/QALY, and $64,793.71/QALY, resp.). A partial course of ACS was not cost-effective. While ACS was the consistently dominant strategy for acute respiratory outcomes, all models were sensitive to changes in variables associated with chronic respiratory disease. Conclusions. Our findings suggest that the administration of ACS to patients at risk of imminent delivery 34-36 weeks could significantly reduce the cost and acute morbidity associated with late-preterm birth.",2012-01-10222,23326677,ISRN Obstet Gynecol,Jamie A Bastek,2012,2012 /,491595,No,23326677,"Jamie A Bastek; Holly Langmuir; Laxmi A Kondapalli; Emmanuelle Par?; Joanna E Adamczak; Sindhu K Srinivas; Antenatal corticosteroids for late-preterm infants: a decision-analytic and economic analysis, ISRN Obstet Gynecol, ; 2012():2090-4444; 491595",QALY,Not Stated,Not Stated,Not Stated,Antenatal corticosteroids (ACS) at 36 weeks vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,Not Stated,64793.71,United States,2011,74550.54
10551,Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective,"Major orthopaedic surgery, such as total hip replacement (THR) and total knee replacement (TKR), is associated with an increased risk of venous thromboembolism (VTE).Clinical trials have demonstrated the efficacy of rivaroxaban, a once-daily, orally administered Factor Xa inhibitor, for the prevention of VTE in patients undergoing THR or TKR. This analysis evaluated the cost effectiveness of rivaroxaban compared with enoxaparin, from a U.S. payer's perspective.A decision-analytic model was developed to compare the costs and outcomes associated with rivaroxaban and enoxaparin for the prevention of VTE. The model replicated short-term clinical outcomes from the phase III RECORD trials. RECORD1 and RECORD2 compared rivaroxaban 10?mg daily (qd), given for 35 days, with enoxaparin 40?mg qd, given for 35 days or 10 to 14 days, respectively, in patients undergoing THR. RECORD3 compared 10?mg of rivaroxaban qd for 10 to 14 days versus 40?mg of enoxaparin qd for 10 to 14 days in patients undergoing TKR. The decision-analytic model also included data on long-term complications and sequelae as captured in observational studies and databases. It also included direct year 2010 medical costs over 1-year and 5-year time horizons. A series of sensitivity analyses were performed to determine the impact of different factors on the results of the model. Results of the cost-effectiveness analysis were reported in terms of symptomatic VTE events avoided.Rivaroxaban was associated with cost savings of $US 511.93 per patient and prevented an average of 0.0145 symptomatic VTE events per patient in the THR population, compared with enoxaparin. For a TKR population, 10 to 14 days of rivaroxaban prophylaxis was associated with cost savings of $US 465.74 and prevented an average 0.0193 symptomatic VTE events per patient. Sensitivity analysis suggested that the results of the model were robust, with cost savings ranging from $US 133.96-629.57 in the THR population and $US 293.01-848.68 in the TKR population, depending on the variables used. Sensitivity analysis also suggested that the economic profile of rivaroxaban is improved when the time horizon of the model is extended from 1 year to 5 years. A probabilistic sensitivity analysis confirmed the findings of baseline results, showing that rivaroxaban was less costly and more effective in all model simulations for both populations.This decision-analytic model analysis, from the U.S. payer's perspective, concluded that rivaroxaban may be cost saving in both the THR and the TKR populations, when compared with enoxaparin in the U.S.",2012-01-10257,22187932,Pharmacoeconomics,Aurea Duran,2012,30 / 2,87-101,Yes,22187932,"Aurea Duran; Nishan Sengupta; Alexander Diamantopoulos; Fiona Forster; Louis Kwong; Michael Lees; Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective, Pharmacoeconomics, ; 30(2):1179-2027; 87-101",QALY,Not Stated,Not Stated,Not Stated,Rivaroxaban (10 mg daily) vs. Enoxaparin (40 mg daily),Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,-269436.84,United States,2010,-319795
10552,Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective,"Major orthopaedic surgery, such as total hip replacement (THR) and total knee replacement (TKR), is associated with an increased risk of venous thromboembolism (VTE).Clinical trials have demonstrated the efficacy of rivaroxaban, a once-daily, orally administered Factor Xa inhibitor, for the prevention of VTE in patients undergoing THR or TKR. This analysis evaluated the cost effectiveness of rivaroxaban compared with enoxaparin, from a U.S. payer's perspective.A decision-analytic model was developed to compare the costs and outcomes associated with rivaroxaban and enoxaparin for the prevention of VTE. The model replicated short-term clinical outcomes from the phase III RECORD trials. RECORD1 and RECORD2 compared rivaroxaban 10?mg daily (qd), given for 35 days, with enoxaparin 40?mg qd, given for 35 days or 10 to 14 days, respectively, in patients undergoing THR. RECORD3 compared 10?mg of rivaroxaban qd for 10 to 14 days versus 40?mg of enoxaparin qd for 10 to 14 days in patients undergoing TKR. The decision-analytic model also included data on long-term complications and sequelae as captured in observational studies and databases. It also included direct year 2010 medical costs over 1-year and 5-year time horizons. A series of sensitivity analyses were performed to determine the impact of different factors on the results of the model. Results of the cost-effectiveness analysis were reported in terms of symptomatic VTE events avoided.Rivaroxaban was associated with cost savings of $US 511.93 per patient and prevented an average of 0.0145 symptomatic VTE events per patient in the THR population, compared with enoxaparin. For a TKR population, 10 to 14 days of rivaroxaban prophylaxis was associated with cost savings of $US 465.74 and prevented an average 0.0193 symptomatic VTE events per patient. Sensitivity analysis suggested that the results of the model were robust, with cost savings ranging from $US 133.96-629.57 in the THR population and $US 293.01-848.68 in the TKR population, depending on the variables used. Sensitivity analysis also suggested that the economic profile of rivaroxaban is improved when the time horizon of the model is extended from 1 year to 5 years. A probabilistic sensitivity analysis confirmed the findings of baseline results, showing that rivaroxaban was less costly and more effective in all model simulations for both populations.This decision-analytic model analysis, from the U.S. payer's perspective, concluded that rivaroxaban may be cost saving in both the THR and the TKR populations, when compared with enoxaparin in the U.S.",2012-01-10257,22187932,Pharmacoeconomics,Aurea Duran,2012,30 / 2,87-101,Yes,22187932,"Aurea Duran; Nishan Sengupta; Alexander Diamantopoulos; Fiona Forster; Louis Kwong; Michael Lees; Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective, Pharmacoeconomics, ; 30(2):1179-2027; 87-101",QALY,Not Stated,Not Stated,Not Stated,Rivaroxaban (10 mg daily) vs. Enoxaparin (40 mg daily),Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,-194058.31,United States,2010,-230328.11
10553,Economic evaluation of the use of exogenous pulmonary surfactants in preterm newborns in a Mexican population,"To estimate the cost-effectiveness ratio of surfactant rescue treatment of premature infants with respiratory distress syndrome (RDS) who are covered by the Medical Insurance for a New Generation.A cost-effectiveness evaluation was conducted from the third-payer perspective. Comparisons were made between the use of bovine surfactant (BS) therapy and without BS therapy. A decision tree model with a lifetime horizon was used where the measurements of effectiveness were life years gained (LYG) and quality-adjusted life years (QALYs). A 5% discount rate was considered for costs and health outcomes. All costs are expressed in Mexican pesos 2009.Incremental cost-effectiveness ratios (ICER) were MXN$136,670 per LYG and MXN$125,250 per QALY.Surfactant therapy was confirmed as a cost-effective strategy in accordance with World Health Organization criteria of three per capita gross domestic product (GDP) per QALY in premature infants with RDS in Mexico.",2012-01-10293,22965446,Salud Publica Mex,Guillermo Salinas-Escudero,2012,54Suppl1 /,S73-81,No,22965446,"Guillermo Salinas-Escudero; Alfonso Reyes-L?pez; Juan Gardu?o-Espinosa; Miguel Angel Villas?s-Keever; Silvia Mart?nez-Valverde; Onofre Mu?oz-Hern?ndez; Economic evaluation of the use of exogenous pulmonary surfactants in preterm newborns in a Mexican population, Salud Publica Mex, ; 54Suppl1():0036-3634; S73-81",QALY,Not Stated,Not Stated,Not Stated,Surfactant rescue treatment with bovine surfactant (BS) therapy vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,125250,Mexico,2009,11215.51
10554,Cost-effectiveness of enhanced depression care after acute coronary syndrome: results from the Coronary Psychosocial Evaluation Studies randomized controlled trial,No abstract available,2012-01-10309,23070196,Arch Intern Med,Joseph A Ladapo,2012,172 / 21,1682-4,No,23070196,"Joseph A Ladapo; Jonathan A Shaffer; Yixin Fang; Siqin Ye; Karina W Davidson; Cost-effectiveness of enhanced depression care after acute coronary syndrome: results from the Coronary Psychosocial Evaluation Studies randomized controlled trial, Arch Intern Med, ; 172(21):0003-9926; 1682-4",QALY,Not Stated,Not Stated,Not Stated,"Enhanced depression care (patient preference for problem-solving psychotherapy, antidepressant use, or both, through the use of a stepped-care algorithm) vs. Usual care",Not Stated,Not Stated,Not Stated,"Female, Male",Full,6 Months,Not Stated,Not Stated,Not Stated,United States,2010,Not Stated
10555,Cost-effectiveness analysis of intrathecal baclofen therapy in Japan,"Intrathecal baclofen (ITB) therapy was approved for health insurance coverage in 2005 for the treatment of patients whose spasticity could not be adequately controlled by conventional therapy, and is currently being used to treat around 300 patients nationwide in Japan. Various reports have examined the efficacy and safety of ITB therapy, but no report has evaluated the patient quality of life and medical costs in Japan. A cost-utility analysis of ITB was conducted by time period in six severely spastic patients admitted to our university hospital between 2005 and 2010 for ITB therapy. The average cost of ITB therapy per quality-adjusted life year (QALY; number of years survival in perfect health) 5 years after surgery was 1,554,428 yen, below the 6 million yen willingness-to-pay threshold for 1 QALY. This study shows that ITB therapy in Japan is an outstanding treatment in medicoeconomic terms.",2012-01-10333,22850496,Neurol Med Chir (Tokyo),Naoyuki Hattori,2012,52 / 7,482-7,No,22850496,"Naoyuki Hattori; Teruyasu Hirayama; Yoichi Katayama; Cost-effectiveness analysis of intrathecal baclofen therapy in Japan, Neurol Med Chir (Tokyo), ; 52(7):1349-8029; 482-7",QALY,Japan,Not Stated,Not Stated,Intrathecal baclfoen therapy vs. Conventional care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,5.00,Not Stated,1554428,Japan,2009,20045.86
10556,Cost-effectiveness analysis of a community health worker intervention for low-income Hispanic adults with diabetes,"The objective of our study was to estimate the long-term cost-effectiveness of a lifestyle modification program led by community health workers (CHWs) for low-income Hispanic adults with type 2 diabetes.We forecasted disease outcomes, quality-adjusted life years (QALYs) gained, and lifetime costs associated with attaining different hemoglobin A1c (A1c) levels. Outcomes were projected 20 years into the future and discounted at a 3.0% rate. Sensitivity analyses were conducted to assess the extent to which our results were dependent on assumptions related to program effectiveness, projected years, discount rates, and costs.The incremental cost-effectiveness ratio of the intervention ranged from $10,995 to $33,319 per QALY gained when compared with usual care. The intervention was particularly cost-effective for adults with high glycemic levels (A1c > 9%). The results are robust to changes in multiple parameters.The CHW program was cost-effective. This study adds to the evidence that culturally sensitive lifestyle modification programs to control diabetes can be a cost-effective way to improve health among Hispanics with diabetes, particularly among those with high A1c levels.",2012-01-10349,22916995,Prev Chronic Dis,H Shelton Brown,2012,9 /,E140,No,22916995,"H Shelton Brown; Kimberly J Wilson; Jos A Pagn; Christine M Arcari; Martha Martinez; Kirk Smith; Belinda Reininger; Cost-effectiveness analysis of a community health worker intervention for low-income Hispanic adults with diabetes, Prev Chronic Dis, ; 9():1545-1151; E140",QALY,Not Stated,Not Stated,Not Stated,"Lifestyle midofication program led by community health workers (CHWs) (provide individualized guidance, one-on-one diabetes education, counseling aimed at increasing participants ability, self-efficacy to manage their diabetes, improve their nutrition, and lose weight) vs. Standard of care",Not Stated,Not Stated,30 Years,"Female, Male",Full,20 Years,3.00,3.00,33319,United States,2010,39546.37
10557,Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis,"There are limited data evaluating the cost-effectiveness of gastric cancer screening using endoscopy or upper gastrointestinal x-ray in the general population.To evaluate the cost- effectiveness of population-based screening for gastric cancer in South Korea by decision analysis.A time-dependent Markov model for gastric cancer was constructed for healthy adults 30 years of age and older, and a deterministic sensitivity analysis was performed. Cost-utility analysis with multiple strategies was conducted to compare the costs and effects of 13 different screening alternatives with respect to the following eligibility criteria: age at the beginning of screening, screening interval, and screening method. The main outcome measurement was the incremental cost-effectiveness ratio.The results revealed that annual endoscopic screening from ages 50-80 was the most cost-effective for the male population. In the females, biennial endoscopy screening from ages 50-80 was calculated as the most cost-effective strategy among the 12 screening alternatives. The most cost-effective screening strategy may be adjustable according to the screening costs and the distribution of cancer stage at screening. The limitation was that effectiveness data were obtained from published sources.Using the threshold of $19,162 per quality-adjusted life year on the basis of the Korean gross domestic product (2008), as suggested by the World Health Organization, endoscopic gastric cancer screening starting at the age of 50 years was highly cost-effective in the Korean population. The national recommendation for gastric cancer screening should consider the starting age of screening, the screening interval, and the screening modality.",2012-01-10358,22938448,Asian Pac J Cancer Prev,Hoo-Sun Chang,2012,13 / 6,2721-8,No,22938448,"Hoo-Sun Chang; Eun-Cheol Park; Woojin Chung; Chung Mo Nam; Kui Son Choi; Eun Cho; Woo-Hyun Cho; Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis, Asian Pac J Cancer Prev, ; 13(6):1513-7368; 2721-8",QALY,Not Stated,Not Stated,Not Stated,Endoscopy screening strategy for gastric cancer annually in men age 50-80 years vs. None,Not Stated,80 Years,30 Years,Male,Full,Lifetime,3.00,3.00,4979,United States,2008,5985.15
10558,Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis,"There are limited data evaluating the cost-effectiveness of gastric cancer screening using endoscopy or upper gastrointestinal x-ray in the general population.To evaluate the cost- effectiveness of population-based screening for gastric cancer in South Korea by decision analysis.A time-dependent Markov model for gastric cancer was constructed for healthy adults 30 years of age and older, and a deterministic sensitivity analysis was performed. Cost-utility analysis with multiple strategies was conducted to compare the costs and effects of 13 different screening alternatives with respect to the following eligibility criteria: age at the beginning of screening, screening interval, and screening method. The main outcome measurement was the incremental cost-effectiveness ratio.The results revealed that annual endoscopic screening from ages 50-80 was the most cost-effective for the male population. In the females, biennial endoscopy screening from ages 50-80 was calculated as the most cost-effective strategy among the 12 screening alternatives. The most cost-effective screening strategy may be adjustable according to the screening costs and the distribution of cancer stage at screening. The limitation was that effectiveness data were obtained from published sources.Using the threshold of $19,162 per quality-adjusted life year on the basis of the Korean gross domestic product (2008), as suggested by the World Health Organization, endoscopic gastric cancer screening starting at the age of 50 years was highly cost-effective in the Korean population. The national recommendation for gastric cancer screening should consider the starting age of screening, the screening interval, and the screening modality.",2012-01-10358,22938448,Asian Pac J Cancer Prev,Hoo-Sun Chang,2012,13 / 6,2721-8,No,22938448,"Hoo-Sun Chang; Eun-Cheol Park; Woojin Chung; Chung Mo Nam; Kui Son Choi; Eun Cho; Woo-Hyun Cho; Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis, Asian Pac J Cancer Prev, ; 13(6):1513-7368; 2721-8",QALY,Not Stated,Not Stated,Not Stated,Endoscopy screening strategy for gastric cancer annually in adults 40 to 80 years vs. Endoscopy screening strategy annually in men aged 50 to 80 years,Not Stated,80 Years,30 Years,Male,Full,Lifetime,3.00,3.00,20480,United States,2008,24618.56
10559,Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis,"There are limited data evaluating the cost-effectiveness of gastric cancer screening using endoscopy or upper gastrointestinal x-ray in the general population.To evaluate the cost- effectiveness of population-based screening for gastric cancer in South Korea by decision analysis.A time-dependent Markov model for gastric cancer was constructed for healthy adults 30 years of age and older, and a deterministic sensitivity analysis was performed. Cost-utility analysis with multiple strategies was conducted to compare the costs and effects of 13 different screening alternatives with respect to the following eligibility criteria: age at the beginning of screening, screening interval, and screening method. The main outcome measurement was the incremental cost-effectiveness ratio.The results revealed that annual endoscopic screening from ages 50-80 was the most cost-effective for the male population. In the females, biennial endoscopy screening from ages 50-80 was calculated as the most cost-effective strategy among the 12 screening alternatives. The most cost-effective screening strategy may be adjustable according to the screening costs and the distribution of cancer stage at screening. The limitation was that effectiveness data were obtained from published sources.Using the threshold of $19,162 per quality-adjusted life year on the basis of the Korean gross domestic product (2008), as suggested by the World Health Organization, endoscopic gastric cancer screening starting at the age of 50 years was highly cost-effective in the Korean population. The national recommendation for gastric cancer screening should consider the starting age of screening, the screening interval, and the screening modality.",2012-01-10358,22938448,Asian Pac J Cancer Prev,Hoo-Sun Chang,2012,13 / 6,2721-8,No,22938448,"Hoo-Sun Chang; Eun-Cheol Park; Woojin Chung; Chung Mo Nam; Kui Son Choi; Eun Cho; Woo-Hyun Cho; Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis, Asian Pac J Cancer Prev, ; 13(6):1513-7368; 2721-8",QALY,Not Stated,Not Stated,Not Stated,Endoscopy screening strategy for gastric cancer annually in adults ages 30 to 80 years vs. Endoscopy screening strategy annually in men aged 40 to 80 years,Not Stated,80 Years,30 Years,Female,Full,Lifetime,3.00,3.00,81294,United States,2008,97721.73
10560,Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis,"There are limited data evaluating the cost-effectiveness of gastric cancer screening using endoscopy or upper gastrointestinal x-ray in the general population.To evaluate the cost- effectiveness of population-based screening for gastric cancer in South Korea by decision analysis.A time-dependent Markov model for gastric cancer was constructed for healthy adults 30 years of age and older, and a deterministic sensitivity analysis was performed. Cost-utility analysis with multiple strategies was conducted to compare the costs and effects of 13 different screening alternatives with respect to the following eligibility criteria: age at the beginning of screening, screening interval, and screening method. The main outcome measurement was the incremental cost-effectiveness ratio.The results revealed that annual endoscopic screening from ages 50-80 was the most cost-effective for the male population. In the females, biennial endoscopy screening from ages 50-80 was calculated as the most cost-effective strategy among the 12 screening alternatives. The most cost-effective screening strategy may be adjustable according to the screening costs and the distribution of cancer stage at screening. The limitation was that effectiveness data were obtained from published sources.Using the threshold of $19,162 per quality-adjusted life year on the basis of the Korean gross domestic product (2008), as suggested by the World Health Organization, endoscopic gastric cancer screening starting at the age of 50 years was highly cost-effective in the Korean population. The national recommendation for gastric cancer screening should consider the starting age of screening, the screening interval, and the screening modality.",2012-01-10358,22938448,Asian Pac J Cancer Prev,Hoo-Sun Chang,2012,13 / 6,2721-8,No,22938448,"Hoo-Sun Chang; Eun-Cheol Park; Woojin Chung; Chung Mo Nam; Kui Son Choi; Eun Cho; Woo-Hyun Cho; Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis, Asian Pac J Cancer Prev, ; 13(6):1513-7368; 2721-8",QALY,Not Stated,Not Stated,Not Stated,Endoscopy screening strategy for gastric cancer every two years in ages 50 to 80 years vs. None,Not Stated,80 Years,30 Years,Female,Full,Lifetime,3.00,3.00,11378,United States,2008,13677.24
10561,Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis,"There are limited data evaluating the cost-effectiveness of gastric cancer screening using endoscopy or upper gastrointestinal x-ray in the general population.To evaluate the cost- effectiveness of population-based screening for gastric cancer in South Korea by decision analysis.A time-dependent Markov model for gastric cancer was constructed for healthy adults 30 years of age and older, and a deterministic sensitivity analysis was performed. Cost-utility analysis with multiple strategies was conducted to compare the costs and effects of 13 different screening alternatives with respect to the following eligibility criteria: age at the beginning of screening, screening interval, and screening method. The main outcome measurement was the incremental cost-effectiveness ratio.The results revealed that annual endoscopic screening from ages 50-80 was the most cost-effective for the male population. In the females, biennial endoscopy screening from ages 50-80 was calculated as the most cost-effective strategy among the 12 screening alternatives. The most cost-effective screening strategy may be adjustable according to the screening costs and the distribution of cancer stage at screening. The limitation was that effectiveness data were obtained from published sources.Using the threshold of $19,162 per quality-adjusted life year on the basis of the Korean gross domestic product (2008), as suggested by the World Health Organization, endoscopic gastric cancer screening starting at the age of 50 years was highly cost-effective in the Korean population. The national recommendation for gastric cancer screening should consider the starting age of screening, the screening interval, and the screening modality.",2012-01-10358,22938448,Asian Pac J Cancer Prev,Hoo-Sun Chang,2012,13 / 6,2721-8,No,22938448,"Hoo-Sun Chang; Eun-Cheol Park; Woojin Chung; Chung Mo Nam; Kui Son Choi; Eun Cho; Woo-Hyun Cho; Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis, Asian Pac J Cancer Prev, ; 13(6):1513-7368; 2721-8",QALY,Not Stated,Not Stated,Not Stated,Endoscopy screening annually for gastric cancer in ages 50 to 80 years vs. Endoscopy screening strategy every two years in ages 50 to 80 years,Not Stated,80 Years,30 Years,Female,Full,Lifetime,3.00,3.00,12180,United States,2008,14641.31
10562,Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis,"There are limited data evaluating the cost-effectiveness of gastric cancer screening using endoscopy or upper gastrointestinal x-ray in the general population.To evaluate the cost- effectiveness of population-based screening for gastric cancer in South Korea by decision analysis.A time-dependent Markov model for gastric cancer was constructed for healthy adults 30 years of age and older, and a deterministic sensitivity analysis was performed. Cost-utility analysis with multiple strategies was conducted to compare the costs and effects of 13 different screening alternatives with respect to the following eligibility criteria: age at the beginning of screening, screening interval, and screening method. The main outcome measurement was the incremental cost-effectiveness ratio.The results revealed that annual endoscopic screening from ages 50-80 was the most cost-effective for the male population. In the females, biennial endoscopy screening from ages 50-80 was calculated as the most cost-effective strategy among the 12 screening alternatives. The most cost-effective screening strategy may be adjustable according to the screening costs and the distribution of cancer stage at screening. The limitation was that effectiveness data were obtained from published sources.Using the threshold of $19,162 per quality-adjusted life year on the basis of the Korean gross domestic product (2008), as suggested by the World Health Organization, endoscopic gastric cancer screening starting at the age of 50 years was highly cost-effective in the Korean population. The national recommendation for gastric cancer screening should consider the starting age of screening, the screening interval, and the screening modality.",2012-01-10358,22938448,Asian Pac J Cancer Prev,Hoo-Sun Chang,2012,13 / 6,2721-8,No,22938448,"Hoo-Sun Chang; Eun-Cheol Park; Woojin Chung; Chung Mo Nam; Kui Son Choi; Eun Cho; Woo-Hyun Cho; Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis, Asian Pac J Cancer Prev, ; 13(6):1513-7368; 2721-8",QALY,Not Stated,Not Stated,Not Stated,Endoscopy screening annually for gastric cancer in ages 40 to 80 years vs. Endoscopy screening strategy annually in ages 50 to 80 years,Not Stated,80 Years,30 Years,Female,Full,Lifetime,3.00,3.00,22283,United States,2008,26785.9
10563,Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis,"There are limited data evaluating the cost-effectiveness of gastric cancer screening using endoscopy or upper gastrointestinal x-ray in the general population.To evaluate the cost- effectiveness of population-based screening for gastric cancer in South Korea by decision analysis.A time-dependent Markov model for gastric cancer was constructed for healthy adults 30 years of age and older, and a deterministic sensitivity analysis was performed. Cost-utility analysis with multiple strategies was conducted to compare the costs and effects of 13 different screening alternatives with respect to the following eligibility criteria: age at the beginning of screening, screening interval, and screening method. The main outcome measurement was the incremental cost-effectiveness ratio.The results revealed that annual endoscopic screening from ages 50-80 was the most cost-effective for the male population. In the females, biennial endoscopy screening from ages 50-80 was calculated as the most cost-effective strategy among the 12 screening alternatives. The most cost-effective screening strategy may be adjustable according to the screening costs and the distribution of cancer stage at screening. The limitation was that effectiveness data were obtained from published sources.Using the threshold of $19,162 per quality-adjusted life year on the basis of the Korean gross domestic product (2008), as suggested by the World Health Organization, endoscopic gastric cancer screening starting at the age of 50 years was highly cost-effective in the Korean population. The national recommendation for gastric cancer screening should consider the starting age of screening, the screening interval, and the screening modality.",2012-01-10358,22938448,Asian Pac J Cancer Prev,Hoo-Sun Chang,2012,13 / 6,2721-8,No,22938448,"Hoo-Sun Chang; Eun-Cheol Park; Woojin Chung; Chung Mo Nam; Kui Son Choi; Eun Cho; Woo-Hyun Cho; Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis, Asian Pac J Cancer Prev, ; 13(6):1513-7368; 2721-8",QALY,Not Stated,Not Stated,Not Stated,Endoscopy screening annually for gastric cancer in ages 30 to 80 years vs. Endoscopy screening strategy annually in ages 40 to 80 years,Not Stated,80 Years,30 Years,Female,Full,Lifetime,3.00,3.00,50033,United States,2008,60143.57
10564,Markov's modeling for screening strategies for colorectal cancer,"Economic decision models are being increasingly used to assess medical interventions. Advances in this field are mainly due to enhanced processing capacity of computers, availability of specific software to perform the necessary tasks, and refined mathematical techniques. We here estimated the incremental cost-effectiveness of ten strategies for colon cancer screening, as well as no screening, incorporating quality of life, noncompliance and data on the costs and profit of chemotherapy in Iran. We used a Markov model to measure the costs and quality-adjusted life expectancy of a 50-year-old average-risk Iranian without screening and with screening by each test. In this paper, we tested the model with data from the Ministry of Health and published literature. We considered costs from the perspective of a health insurance organization, with inflation to 2011, the Iranian Rial being converted into US dollars. We focused on three tests for the 10 strategies considered currently being used for population screening in some Iranians provinces (Kerman, Golestan Mazandaran, Ardabil, and Tehran): low-sensitivity guaiac fecal occult blood test, performed annually; fecal immunochemical test, performed annually; and colonoscopy, performed every 10 years. These strategies reduced the incidence of colorectal cancer by 39%, 60% and 76%, and mortality by 50%, 69% and 78%, respectively, compared with no screening. These approaches generated ICER (incremental cost-effectiveness ratios) of $9067, $654 and $8700 per QALY (quality-adjusted life year), respectively. Sensitivity analyses were conducted to assess the influence of various scales on the economic evaluation of screening. The results were sensitive to probabilistic sensitivity analysis. Colonoscopy every ten years yielded the greatest net health value. Screening for colon cancer is economical and cost-effective over conventional levels of WTP8.",2012-01-10374,23244122,Asian Pac J Cancer Prev,Mohsen Barouni,2012,13 / 10,5125-9,No,23244122,"Mohsen Barouni; Mohammad Hassan Larizadeh; Asma Sabermahani; Hossien Ghaderi; Markov's modeling for screening strategies for colorectal cancer, Asian Pac J Cancer Prev, ; 13(10):1513-7368; 5125-9",QALY,Not Stated,Not Stated,Not Stated,Low-sensitivity guaiac fecal occult blood test screening strategy performed annually vs. None,Not Stated,50 Years,50 Years,"Female, Male",Full,Lifetime,5.00,5.00,10533.33,United States,2011,12119.48
10565,Markov's modeling for screening strategies for colorectal cancer,"Economic decision models are being increasingly used to assess medical interventions. Advances in this field are mainly due to enhanced processing capacity of computers, availability of specific software to perform the necessary tasks, and refined mathematical techniques. We here estimated the incremental cost-effectiveness of ten strategies for colon cancer screening, as well as no screening, incorporating quality of life, noncompliance and data on the costs and profit of chemotherapy in Iran. We used a Markov model to measure the costs and quality-adjusted life expectancy of a 50-year-old average-risk Iranian without screening and with screening by each test. In this paper, we tested the model with data from the Ministry of Health and published literature. We considered costs from the perspective of a health insurance organization, with inflation to 2011, the Iranian Rial being converted into US dollars. We focused on three tests for the 10 strategies considered currently being used for population screening in some Iranians provinces (Kerman, Golestan Mazandaran, Ardabil, and Tehran): low-sensitivity guaiac fecal occult blood test, performed annually; fecal immunochemical test, performed annually; and colonoscopy, performed every 10 years. These strategies reduced the incidence of colorectal cancer by 39%, 60% and 76%, and mortality by 50%, 69% and 78%, respectively, compared with no screening. These approaches generated ICER (incremental cost-effectiveness ratios) of $9067, $654 and $8700 per QALY (quality-adjusted life year), respectively. Sensitivity analyses were conducted to assess the influence of various scales on the economic evaluation of screening. The results were sensitive to probabilistic sensitivity analysis. Colonoscopy every ten years yielded the greatest net health value. Screening for colon cancer is economical and cost-effective over conventional levels of WTP8.",2012-01-10374,23244122,Asian Pac J Cancer Prev,Mohsen Barouni,2012,13 / 10,5125-9,No,23244122,"Mohsen Barouni; Mohammad Hassan Larizadeh; Asma Sabermahani; Hossien Ghaderi; Markov's modeling for screening strategies for colorectal cancer, Asian Pac J Cancer Prev, ; 13(10):1513-7368; 5125-9",QALY,Not Stated,Not Stated,Not Stated,Fecal immunochemical test performed annually vs. Low-sensitivity guaiac fecal occult blood test screening strategy performed annually,Not Stated,50 Years,50 Years,"Female, Male",Full,Lifetime,5.00,5.00,550,United States,2011,632.82
10566,Markov's modeling for screening strategies for colorectal cancer,"Economic decision models are being increasingly used to assess medical interventions. Advances in this field are mainly due to enhanced processing capacity of computers, availability of specific software to perform the necessary tasks, and refined mathematical techniques. We here estimated the incremental cost-effectiveness of ten strategies for colon cancer screening, as well as no screening, incorporating quality of life, noncompliance and data on the costs and profit of chemotherapy in Iran. We used a Markov model to measure the costs and quality-adjusted life expectancy of a 50-year-old average-risk Iranian without screening and with screening by each test. In this paper, we tested the model with data from the Ministry of Health and published literature. We considered costs from the perspective of a health insurance organization, with inflation to 2011, the Iranian Rial being converted into US dollars. We focused on three tests for the 10 strategies considered currently being used for population screening in some Iranians provinces (Kerman, Golestan Mazandaran, Ardabil, and Tehran): low-sensitivity guaiac fecal occult blood test, performed annually; fecal immunochemical test, performed annually; and colonoscopy, performed every 10 years. These strategies reduced the incidence of colorectal cancer by 39%, 60% and 76%, and mortality by 50%, 69% and 78%, respectively, compared with no screening. These approaches generated ICER (incremental cost-effectiveness ratios) of $9067, $654 and $8700 per QALY (quality-adjusted life year), respectively. Sensitivity analyses were conducted to assess the influence of various scales on the economic evaluation of screening. The results were sensitive to probabilistic sensitivity analysis. Colonoscopy every ten years yielded the greatest net health value. Screening for colon cancer is economical and cost-effective over conventional levels of WTP8.",2012-01-10374,23244122,Asian Pac J Cancer Prev,Mohsen Barouni,2012,13 / 10,5125-9,No,23244122,"Mohsen Barouni; Mohammad Hassan Larizadeh; Asma Sabermahani; Hossien Ghaderi; Markov's modeling for screening strategies for colorectal cancer, Asian Pac J Cancer Prev, ; 13(10):1513-7368; 5125-9",QALY,Not Stated,Not Stated,Not Stated,Colonoscopy performed every 10 years vs. Fecal immunochemical test performed annually,Not Stated,50 Years,50 Years,"Female, Male",Full,Lifetime,5.00,5.00,4600,United States,2011,5292.68
10567,The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country's approach (England) to that of a middle-income one (Colombia),"Determining the cost-effectiveness of enzyme replacement therapy (ERT) for the classical infantile form of Pompe disease (complete acid a-glucosidase deficiency-related) in two different settings: England and Colombia. Pompe disease is very rare (1:40,000 births incidence).A literature review was made and historic databases searched for National Health Service (NHS) reimbursed costs in England and by health insurers in Colombia; expert opinion was elicited. Two Markov models were constructed for comparing both countries; alive with symptoms and dead were the transition states used. Patients aged < 6 months receiving ERT were assumed to have 75 % survival rate and better health-related quality of life (HR-QoL) compared to those without treatment (0.700 HR- QoL using the EQ-5D scale).The incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained was ?234,307.7 for England and ?109,991 for Colombia. Uncertainty about Anal HR-QoL with ERT, disease progression and cost from palliative care had the biggest impact on the ICER in both models. If ERT costs were reduced to 10,000 times per dose and HR-QoL was 0.750-0.820 ICER, then ?165,000 could be attainable for England and ?65,000 for Colombia. Transaction costs per case in Colombia were high.ERT was more effective than no ERT in treating infantile Pompe disease, but high levels of uncertainty still remain about survival and progression rates and QoL in the long-run. ICERs were high compared to CE thresholds. Manufacturers' ERT costs and monopoly had a major impact on Anal CEA results.",2012-01-10383,23250322,Rev Salud Publica (Bogota),H?ctor E Castro-Jaramillo,2012,14 / 1,143-55,No,23250322,"H?ctor E Castro-Jaramillo; The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country's approach (England) to that of a middle-income one (Colombia), Rev Salud Publica (Bogota), ; 14(1):0124-0064; 143-55",QALY,Not Stated,Not Stated,Not Stated,Enzyme replacement therapy vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,5.00,5.00,234307,United Kingdom,2010,429325.78
10568,The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country's approach (England) to that of a middle-income one (Colombia),"Determining the cost-effectiveness of enzyme replacement therapy (ERT) for the classical infantile form of Pompe disease (complete acid a-glucosidase deficiency-related) in two different settings: England and Colombia. Pompe disease is very rare (1:40,000 births incidence).A literature review was made and historic databases searched for National Health Service (NHS) reimbursed costs in England and by health insurers in Colombia; expert opinion was elicited. Two Markov models were constructed for comparing both countries; alive with symptoms and dead were the transition states used. Patients aged < 6 months receiving ERT were assumed to have 75 % survival rate and better health-related quality of life (HR-QoL) compared to those without treatment (0.700 HR- QoL using the EQ-5D scale).The incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained was ?234,307.7 for England and ?109,991 for Colombia. Uncertainty about Anal HR-QoL with ERT, disease progression and cost from palliative care had the biggest impact on the ICER in both models. If ERT costs were reduced to 10,000 times per dose and HR-QoL was 0.750-0.820 ICER, then ?165,000 could be attainable for England and ?65,000 for Colombia. Transaction costs per case in Colombia were high.ERT was more effective than no ERT in treating infantile Pompe disease, but high levels of uncertainty still remain about survival and progression rates and QoL in the long-run. ICERs were high compared to CE thresholds. Manufacturers' ERT costs and monopoly had a major impact on Anal CEA results.",2012-01-10383,23250322,Rev Salud Publica (Bogota),H?ctor E Castro-Jaramillo,2012,14 / 1,143-55,No,23250322,"H?ctor E Castro-Jaramillo; The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country's approach (England) to that of a middle-income one (Colombia), Rev Salud Publica (Bogota), ; 14(1):0124-0064; 143-55",QALY,Not Stated,Not Stated,Not Stated,Enzyme replacement therapy vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,5.00,5.00,109991,United Kingdom,2010,201538.89
10569,Cost-effectiveness analysis of a system-based approach for managing neonatal jaundice and preventing kernicterus in Ontario,"To evaluate the incremental cost-effectiveness of a system-based approach for the management of neonatal jaundice and the prevention of kernicterus in term and late-preterm (=35 weeks) infants, compared with the traditional practice based on visual inspection and selected bilirubin testing.Two hypothetical cohorts of 150,000 term and late-preterm neonates were used to compare the costs and outcomes associated with the use of a system-based or traditional practice approach. Data for the evaluation were obtained from the case costing centre at a large teaching hospital in Ontario, supplemented by data from the literature.The per child cost for the system-based approach cohort was $176, compared with $173 in the traditional practice cohort. The higher cost associated with the system-based cohort reflects increased costs for predischarge screening and treatment and increased postdischarge follow-up visits. These costs are partially offset by reduced costs from fewer emergency room visits, hospital readmissions and kernicterus cases. Compared with the traditional approach, the cost to prevent one kernicterus case using the system-based approach was $570,496, the cost per life year gained was $26,279, and the cost per quality-adjusted life year gained was $65,698.The cost to prevent one kernicterus case using the system-based approach is much lower than previously reported in the literature.",2012-01-10390,23277747,Paediatr Child Health,Bin Xie,2012,17 / 1,11-6,No,23277747,"Bin Xie; Orlando da Silva; Greg Zaric; Cost-effectiveness analysis of a system-based approach for managing neonatal jaundice and preventing kernicterus in Ontario, Paediatr Child Health, ; 17(1):1205-7088; 11-6",QALY,Canada,Not Stated,Not Stated,System based approach for the management of neonatal jaundice and the prevention of kernicterus vs. Traditional practice based on visual inspection and selected bilirubin testing,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,Not Stated,Not Stated,65698,Canada,2008,74564.17
10570,Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung,"Patients with epidermal growth factor receptor (EGFR) mutation-positive stage IV adenocarcinoma have improved survival with tyrosine kinase inhibitor (TKI) treatments, but the cost effectiveness of personalized first-line therapy using EGFR mutation testing is unknown.We created a decision analytic model comparing the costs and effects of platinum combination chemotherapy with personalized therapy in which patients with EGFR mutation-positive tumors were treated with erlotinib. We used two testing strategies: testing only those with tissue available and performing a repeat biopsy if tissue was not available versus three nontargeted chemotherapy regimens (ie, carboplatin and paclitaxel; carboplatin and pemetrexed; and carboplatin, pemetrexed, and bevacizumab).Compared with a carboplatin plus paclitaxel regimen, targeted therapy based on testing available tissue yielded an incremental cost-effectiveness ratio (ICER) of $110,644 per quality-adjusted life year (QALY), and the rebiopsy strategy yielded an ICER of $122,219 per QALY. Probabilistic sensitivity analysis revealed substantial uncertainty around these point estimates. With a willingness to pay of $100,000 per QALY, the testing strategy was cost effective 58% of the time, and the rebiopsy strategy was cost effective 54% of the time. Personalized therapy with an EGFR TKI was more favorable when the nontargeted chemotherapy regimen was more expensive. Compared with carboplatin, pemetrexed, and bevacizumab, ICERs were $25,547 per QALY for the testing strategy and $44,036 per QALY for the rebiopsy strategy.Although specific clinical circumstances should guide therapy, our cost-effectiveness analysis supports the strategy of testing for EGFR mutations in patients with stage IV or recurrent adenocarcinoma of the lung, rebiopsying patients if insufficient tissue is available for testing, and treating patients with EGFR mutations with erlotinib as first-line therapy.",2012-01-10391,23277762,J Oncol Pract,Elizabeth A Handorf,2012,8 / 5,267-74,No,23277762,"Elizabeth A Handorf; Sean McElligott; Anil Vachani; Corey J Langer; Mirar Bristol Demeter; Katrina Armstrong; David A Asch; Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung, J Oncol Pract, ; 8(5):1935-469X; 267-74",QALY,Not Stated,Not Stated,Not Stated,Epidermal growth factor receptor (EGFR) mutation testing strategy only on patients with sufficient tumor tissue (test strategy) vs. No testing and all patients were treated with combination chemotherapy with a platinum agent,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Weeks,Not Stated,Not Stated,110644,United States,2009,133477.6
10571,Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung,"Patients with epidermal growth factor receptor (EGFR) mutation-positive stage IV adenocarcinoma have improved survival with tyrosine kinase inhibitor (TKI) treatments, but the cost effectiveness of personalized first-line therapy using EGFR mutation testing is unknown.We created a decision analytic model comparing the costs and effects of platinum combination chemotherapy with personalized therapy in which patients with EGFR mutation-positive tumors were treated with erlotinib. We used two testing strategies: testing only those with tissue available and performing a repeat biopsy if tissue was not available versus three nontargeted chemotherapy regimens (ie, carboplatin and paclitaxel; carboplatin and pemetrexed; and carboplatin, pemetrexed, and bevacizumab).Compared with a carboplatin plus paclitaxel regimen, targeted therapy based on testing available tissue yielded an incremental cost-effectiveness ratio (ICER) of $110,644 per quality-adjusted life year (QALY), and the rebiopsy strategy yielded an ICER of $122,219 per QALY. Probabilistic sensitivity analysis revealed substantial uncertainty around these point estimates. With a willingness to pay of $100,000 per QALY, the testing strategy was cost effective 58% of the time, and the rebiopsy strategy was cost effective 54% of the time. Personalized therapy with an EGFR TKI was more favorable when the nontargeted chemotherapy regimen was more expensive. Compared with carboplatin, pemetrexed, and bevacizumab, ICERs were $25,547 per QALY for the testing strategy and $44,036 per QALY for the rebiopsy strategy.Although specific clinical circumstances should guide therapy, our cost-effectiveness analysis supports the strategy of testing for EGFR mutations in patients with stage IV or recurrent adenocarcinoma of the lung, rebiopsying patients if insufficient tissue is available for testing, and treating patients with EGFR mutations with erlotinib as first-line therapy.",2012-01-10391,23277762,J Oncol Pract,Elizabeth A Handorf,2012,8 / 5,267-74,No,23277762,"Elizabeth A Handorf; Sean McElligott; Anil Vachani; Corey J Langer; Mirar Bristol Demeter; Katrina Armstrong; David A Asch; Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung, J Oncol Pract, ; 8(5):1935-469X; 267-74",QALY,Not Stated,Not Stated,Not Stated,"Epidermal growth factor receptor (EGFR) mutation testing strategy for patients without available tissue, underwent a repeat biopsy to provide tissue for testing (rebiopsy strategy) vs. EGFR mutation testing strategy only on patients with sufficient tumor tissue (test strategy)",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Weeks,Not Stated,Not Stated,122234,United States,2009,147459.43
10572,Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung,"Patients with epidermal growth factor receptor (EGFR) mutation-positive stage IV adenocarcinoma have improved survival with tyrosine kinase inhibitor (TKI) treatments, but the cost effectiveness of personalized first-line therapy using EGFR mutation testing is unknown.We created a decision analytic model comparing the costs and effects of platinum combination chemotherapy with personalized therapy in which patients with EGFR mutation-positive tumors were treated with erlotinib. We used two testing strategies: testing only those with tissue available and performing a repeat biopsy if tissue was not available versus three nontargeted chemotherapy regimens (ie, carboplatin and paclitaxel; carboplatin and pemetrexed; and carboplatin, pemetrexed, and bevacizumab).Compared with a carboplatin plus paclitaxel regimen, targeted therapy based on testing available tissue yielded an incremental cost-effectiveness ratio (ICER) of $110,644 per quality-adjusted life year (QALY), and the rebiopsy strategy yielded an ICER of $122,219 per QALY. Probabilistic sensitivity analysis revealed substantial uncertainty around these point estimates. With a willingness to pay of $100,000 per QALY, the testing strategy was cost effective 58% of the time, and the rebiopsy strategy was cost effective 54% of the time. Personalized therapy with an EGFR TKI was more favorable when the nontargeted chemotherapy regimen was more expensive. Compared with carboplatin, pemetrexed, and bevacizumab, ICERs were $25,547 per QALY for the testing strategy and $44,036 per QALY for the rebiopsy strategy.Although specific clinical circumstances should guide therapy, our cost-effectiveness analysis supports the strategy of testing for EGFR mutations in patients with stage IV or recurrent adenocarcinoma of the lung, rebiopsying patients if insufficient tissue is available for testing, and treating patients with EGFR mutations with erlotinib as first-line therapy.",2012-01-10391,23277762,J Oncol Pract,Elizabeth A Handorf,2012,8 / 5,267-74,No,23277762,"Elizabeth A Handorf; Sean McElligott; Anil Vachani; Corey J Langer; Mirar Bristol Demeter; Katrina Armstrong; David A Asch; Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung, J Oncol Pract, ; 8(5):1935-469X; 267-74",QALY,Not Stated,Not Stated,Not Stated,"Epidermal growth factor receptor (EGFR) mutation testing strategy for patients without available tissue, underwent a repeat biopsy to provide tissue for testing (rebiopsy strategy) followed by treatment with carboplatin plus premetrexed vs. EGFR mutation testing strategy for patients without available tissue, underwent a repeat biopsy to provide tissue for testing (rebiopsy strategy) followed by treatment with premetrexed",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Weeks,Not Stated,Not Stated,180665,United States,2009,217948.84
10573,Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung,"Patients with epidermal growth factor receptor (EGFR) mutation-positive stage IV adenocarcinoma have improved survival with tyrosine kinase inhibitor (TKI) treatments, but the cost effectiveness of personalized first-line therapy using EGFR mutation testing is unknown.We created a decision analytic model comparing the costs and effects of platinum combination chemotherapy with personalized therapy in which patients with EGFR mutation-positive tumors were treated with erlotinib. We used two testing strategies: testing only those with tissue available and performing a repeat biopsy if tissue was not available versus three nontargeted chemotherapy regimens (ie, carboplatin and paclitaxel; carboplatin and pemetrexed; and carboplatin, pemetrexed, and bevacizumab).Compared with a carboplatin plus paclitaxel regimen, targeted therapy based on testing available tissue yielded an incremental cost-effectiveness ratio (ICER) of $110,644 per quality-adjusted life year (QALY), and the rebiopsy strategy yielded an ICER of $122,219 per QALY. Probabilistic sensitivity analysis revealed substantial uncertainty around these point estimates. With a willingness to pay of $100,000 per QALY, the testing strategy was cost effective 58% of the time, and the rebiopsy strategy was cost effective 54% of the time. Personalized therapy with an EGFR TKI was more favorable when the nontargeted chemotherapy regimen was more expensive. Compared with carboplatin, pemetrexed, and bevacizumab, ICERs were $25,547 per QALY for the testing strategy and $44,036 per QALY for the rebiopsy strategy.Although specific clinical circumstances should guide therapy, our cost-effectiveness analysis supports the strategy of testing for EGFR mutations in patients with stage IV or recurrent adenocarcinoma of the lung, rebiopsying patients if insufficient tissue is available for testing, and treating patients with EGFR mutations with erlotinib as first-line therapy.",2012-01-10391,23277762,J Oncol Pract,Elizabeth A Handorf,2012,8 / 5,267-74,No,23277762,"Elizabeth A Handorf; Sean McElligott; Anil Vachani; Corey J Langer; Mirar Bristol Demeter; Katrina Armstrong; David A Asch; Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung, J Oncol Pract, ; 8(5):1935-469X; 267-74",QALY,Not Stated,Not Stated,Not Stated,"Epidermal growth factor receptor (EGFR) mutation testing strategy for patients without available tissue, underwent a repeat biopsy to provide tissue for testing (rebiopsy strategy) followed by treatment with carboplatin, premetrexed and bevacizumab vs. EGFR mutation testing strategy for patients without available tissue, underwent a repeat biopsy to provide tissue for testing (rebiopsy strategy) followed by treatment with premetrexed and carboplatin",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Weeks,Not Stated,Not Stated,359619,United States,2009,433833.57
10574,Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A: results from the botulinum toxin for the upper limb after stroke (BoTULS) trial,"Stroke imposes significant burdens on health services and society, and as such there is a growing need to assess the cost-effectiveness of stroke treatment to ensure maximum benefit is derived from limited resources. This study compared the cost-effectiveness of treating post-stroke upper limb spasticity with botulinum toxin type A plus an upper limb therapy programme against the therapy programme alone. Data on resource use and health outcomes were prospectively collected for 333 patients with post-stroke upper limb spasticity taking part in a randomized trial and combined to estimate the incremental cost per quality adjusted life year (QALY) gained of botulinum toxin type A plus therapy relative to therapy alone. The base case incremental cost-effectiveness ratio (ICER) of botulinum toxin type A plus therapy was ?93,500 per QALY gained. The probability of botulinum toxin type A plus therapy being cost-effective at the England and Wales cost-effectiveness threshold value of ?20,000 per QALY was 0.36. The point estimates of the ICER remained above ?20,000 per QALY for a range of sensitivity analyses, and the probability of botulinum toxin type A plus therapy being cost-effective at the threshold value did not exceed 0.39, regardless of the assumptions made.",2012-01-10399,23342679,Toxins (Basel),Phil Shackley,2012,4 / 12,1415-26,No,23342679,"Phil Shackley; Lisa Shaw; Christopher Price; Frederike van Wijck; Michael Barnes; Laura Graham; Gary A Ford; Nick Steen; Helen Rodgers; Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A: results from the botulinum toxin for the upper limb after stroke (BoTULS) trial, Toxins (Basel), ; 4(12):2072-6651; 1415-26",QALY,Not Stated,Not Stated,Not Stated,Botulinum toxin type A (Dysport) plus a four week upper limb therapy programme comprising of 1 hour of therapy twice weekly vs. Upper limb therapy programme alone,Not Stated,Not Stated,Not Stated,"Female, Male",Full,3 Months,Not Stated,Not Stated,93500,United Kingdom,2007,233652.74
10575,Cost effectiveness of infant vaccination for rotavirus in Canada,"Rotavirus is the main cause of gastroenteritis in Canadian children younger than five years of age, resulting in significant morbidity and cost. The present study provides evidence on the cost effectiveness of two alternative rotavirus vaccinations (RotaTeq [Merck Frosst Canada Ltd, Canada] and Rotarix [GlaxoSmithKline, Canada]) available in Canada.Analysis was conducted through a Markov model that followed a cohort of children from birth to five years of age. Analysis used pertinent data on the natural history of rotavirus and the effects of vaccination. Estimates of heath care costs for children requiring hospitalizations and emergency department visits were derived from the Canadian Immunization Monitoring Program, Active (IMPACT) surveillance, emergency department studies, as well as other Canadian studies. The model estimated the effect of vaccination on costs and quality-adjusted life years (QALYs).The incremental cost per QALY gained from the health care system perspective was $122,000 for RotaTeq and $108,000 for Rotarix. From the societal perspective, both vaccination strategies were dominant - both cost saving and more effective. The cost-effectiveness of vaccination is dependent on the mode of administration, the perspective adopted and the cost of the vaccine.From a societal perspective, a universal vaccination program against rotavirus will be both cost saving and more effective than no vaccination. Becasue the majority of rotavirus infections do not require emergency department visits or hospital admission, from a health care system perspective, a program would not be considered cost effective.",2012-01-10419,23730312,Can J Infect Dis Med Microbiol,Doug Coyle,2012,23 / 2,71-7,No,23730312,"Doug Coyle; Kathryn Coyle; Julie A Bettinger; Scott A Halperin; Wendy Vaudry; David W Scheifele; Nicole Le Saux; Cost effectiveness of infant vaccination for rotavirus in Canada, Can J Infect Dis Med Microbiol, ; 23(2):1712-9532; 71-7",QALY,Canada,Not Stated,Not Stated,Vaccination with RotaTeq to prevent gastroenteritis vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,5.00,5.00,137559.98,Canada,2009,146091.18
10576,Cost effectiveness of infant vaccination for rotavirus in Canada,"Rotavirus is the main cause of gastroenteritis in Canadian children younger than five years of age, resulting in significant morbidity and cost. The present study provides evidence on the cost effectiveness of two alternative rotavirus vaccinations (RotaTeq [Merck Frosst Canada Ltd, Canada] and Rotarix [GlaxoSmithKline, Canada]) available in Canada.Analysis was conducted through a Markov model that followed a cohort of children from birth to five years of age. Analysis used pertinent data on the natural history of rotavirus and the effects of vaccination. Estimates of heath care costs for children requiring hospitalizations and emergency department visits were derived from the Canadian Immunization Monitoring Program, Active (IMPACT) surveillance, emergency department studies, as well as other Canadian studies. The model estimated the effect of vaccination on costs and quality-adjusted life years (QALYs).The incremental cost per QALY gained from the health care system perspective was $122,000 for RotaTeq and $108,000 for Rotarix. From the societal perspective, both vaccination strategies were dominant - both cost saving and more effective. The cost-effectiveness of vaccination is dependent on the mode of administration, the perspective adopted and the cost of the vaccine.From a societal perspective, a universal vaccination program against rotavirus will be both cost saving and more effective than no vaccination. Becasue the majority of rotavirus infections do not require emergency department visits or hospital admission, from a health care system perspective, a program would not be considered cost effective.",2012-01-10419,23730312,Can J Infect Dis Med Microbiol,Doug Coyle,2012,23 / 2,71-7,No,23730312,"Doug Coyle; Kathryn Coyle; Julie A Bettinger; Scott A Halperin; Wendy Vaudry; David W Scheifele; Nicole Le Saux; Cost effectiveness of infant vaccination for rotavirus in Canada, Can J Infect Dis Med Microbiol, ; 23(2):1712-9532; 71-7",QALY,Canada,Not Stated,Not Stated,Vaccination with RotaTeq to prevent gastroenteritis vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,5.00,5.00,-29900,Canada,2009,-31754.34
10577,Cost effectiveness of infant vaccination for rotavirus in Canada,"Rotavirus is the main cause of gastroenteritis in Canadian children younger than five years of age, resulting in significant morbidity and cost. The present study provides evidence on the cost effectiveness of two alternative rotavirus vaccinations (RotaTeq [Merck Frosst Canada Ltd, Canada] and Rotarix [GlaxoSmithKline, Canada]) available in Canada.Analysis was conducted through a Markov model that followed a cohort of children from birth to five years of age. Analysis used pertinent data on the natural history of rotavirus and the effects of vaccination. Estimates of heath care costs for children requiring hospitalizations and emergency department visits were derived from the Canadian Immunization Monitoring Program, Active (IMPACT) surveillance, emergency department studies, as well as other Canadian studies. The model estimated the effect of vaccination on costs and quality-adjusted life years (QALYs).The incremental cost per QALY gained from the health care system perspective was $122,000 for RotaTeq and $108,000 for Rotarix. From the societal perspective, both vaccination strategies were dominant - both cost saving and more effective. The cost-effectiveness of vaccination is dependent on the mode of administration, the perspective adopted and the cost of the vaccine.From a societal perspective, a universal vaccination program against rotavirus will be both cost saving and more effective than no vaccination. Becasue the majority of rotavirus infections do not require emergency department visits or hospital admission, from a health care system perspective, a program would not be considered cost effective.",2012-01-10419,23730312,Can J Infect Dis Med Microbiol,Doug Coyle,2012,23 / 2,71-7,No,23730312,"Doug Coyle; Kathryn Coyle; Julie A Bettinger; Scott A Halperin; Wendy Vaudry; David W Scheifele; Nicole Le Saux; Cost effectiveness of infant vaccination for rotavirus in Canada, Can J Infect Dis Med Microbiol, ; 23(2):1712-9532; 71-7",QALY,Canada,Not Stated,Not Stated,Vaccination with Rotarix to prevent gastroenteritis vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,5.00,5.00,130119.99,Canada,2009,138189.78
10578,Cost effectiveness of infant vaccination for rotavirus in Canada,"Rotavirus is the main cause of gastroenteritis in Canadian children younger than five years of age, resulting in significant morbidity and cost. The present study provides evidence on the cost effectiveness of two alternative rotavirus vaccinations (RotaTeq [Merck Frosst Canada Ltd, Canada] and Rotarix [GlaxoSmithKline, Canada]) available in Canada.Analysis was conducted through a Markov model that followed a cohort of children from birth to five years of age. Analysis used pertinent data on the natural history of rotavirus and the effects of vaccination. Estimates of heath care costs for children requiring hospitalizations and emergency department visits were derived from the Canadian Immunization Monitoring Program, Active (IMPACT) surveillance, emergency department studies, as well as other Canadian studies. The model estimated the effect of vaccination on costs and quality-adjusted life years (QALYs).The incremental cost per QALY gained from the health care system perspective was $122,000 for RotaTeq and $108,000 for Rotarix. From the societal perspective, both vaccination strategies were dominant - both cost saving and more effective. The cost-effectiveness of vaccination is dependent on the mode of administration, the perspective adopted and the cost of the vaccine.From a societal perspective, a universal vaccination program against rotavirus will be both cost saving and more effective than no vaccination. Becasue the majority of rotavirus infections do not require emergency department visits or hospital admission, from a health care system perspective, a program would not be considered cost effective.",2012-01-10419,23730312,Can J Infect Dis Med Microbiol,Doug Coyle,2012,23 / 2,71-7,No,23730312,"Doug Coyle; Kathryn Coyle; Julie A Bettinger; Scott A Halperin; Wendy Vaudry; David W Scheifele; Nicole Le Saux; Cost effectiveness of infant vaccination for rotavirus in Canada, Can J Infect Dis Med Microbiol, ; 23(2):1712-9532; 71-7",QALY,Canada,Not Stated,Not Stated,Vaccination with Rotarix to prevent gastroenteritis vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,5.00,5.00,-47610,Canada,2009,-50562.68
10579,Cost effectiveness of infant vaccination for rotavirus in Canada,"Rotavirus is the main cause of gastroenteritis in Canadian children younger than five years of age, resulting in significant morbidity and cost. The present study provides evidence on the cost effectiveness of two alternative rotavirus vaccinations (RotaTeq [Merck Frosst Canada Ltd, Canada] and Rotarix [GlaxoSmithKline, Canada]) available in Canada.Analysis was conducted through a Markov model that followed a cohort of children from birth to five years of age. Analysis used pertinent data on the natural history of rotavirus and the effects of vaccination. Estimates of heath care costs for children requiring hospitalizations and emergency department visits were derived from the Canadian Immunization Monitoring Program, Active (IMPACT) surveillance, emergency department studies, as well as other Canadian studies. The model estimated the effect of vaccination on costs and quality-adjusted life years (QALYs).The incremental cost per QALY gained from the health care system perspective was $122,000 for RotaTeq and $108,000 for Rotarix. From the societal perspective, both vaccination strategies were dominant - both cost saving and more effective. The cost-effectiveness of vaccination is dependent on the mode of administration, the perspective adopted and the cost of the vaccine.From a societal perspective, a universal vaccination program against rotavirus will be both cost saving and more effective than no vaccination. Becasue the majority of rotavirus infections do not require emergency department visits or hospital admission, from a health care system perspective, a program would not be considered cost effective.",2012-01-10419,23730312,Can J Infect Dis Med Microbiol,Doug Coyle,2012,23 / 2,71-7,No,23730312,"Doug Coyle; Kathryn Coyle; Julie A Bettinger; Scott A Halperin; Wendy Vaudry; David W Scheifele; Nicole Le Saux; Cost effectiveness of infant vaccination for rotavirus in Canada, Can J Infect Dis Med Microbiol, ; 23(2):1712-9532; 71-7",QALY,Canada,Not Stated,Not Stated,Vaccination with Rotarix to prevent gastroenteritis vs. Vaccination with RotaTeq,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,5.00,5.00,Not Stated,Canada,2009,Not Stated
10580,Cost effectiveness of infant vaccination for rotavirus in Canada,"Rotavirus is the main cause of gastroenteritis in Canadian children younger than five years of age, resulting in significant morbidity and cost. The present study provides evidence on the cost effectiveness of two alternative rotavirus vaccinations (RotaTeq [Merck Frosst Canada Ltd, Canada] and Rotarix [GlaxoSmithKline, Canada]) available in Canada.Analysis was conducted through a Markov model that followed a cohort of children from birth to five years of age. Analysis used pertinent data on the natural history of rotavirus and the effects of vaccination. Estimates of heath care costs for children requiring hospitalizations and emergency department visits were derived from the Canadian Immunization Monitoring Program, Active (IMPACT) surveillance, emergency department studies, as well as other Canadian studies. The model estimated the effect of vaccination on costs and quality-adjusted life years (QALYs).The incremental cost per QALY gained from the health care system perspective was $122,000 for RotaTeq and $108,000 for Rotarix. From the societal perspective, both vaccination strategies were dominant - both cost saving and more effective. The cost-effectiveness of vaccination is dependent on the mode of administration, the perspective adopted and the cost of the vaccine.From a societal perspective, a universal vaccination program against rotavirus will be both cost saving and more effective than no vaccination. Becasue the majority of rotavirus infections do not require emergency department visits or hospital admission, from a health care system perspective, a program would not be considered cost effective.",2012-01-10419,23730312,Can J Infect Dis Med Microbiol,Doug Coyle,2012,23 / 2,71-7,No,23730312,"Doug Coyle; Kathryn Coyle; Julie A Bettinger; Scott A Halperin; Wendy Vaudry; David W Scheifele; Nicole Le Saux; Cost effectiveness of infant vaccination for rotavirus in Canada, Can J Infect Dis Med Microbiol, ; 23(2):1712-9532; 71-7",QALY,Canada,Not Stated,Not Stated,Vaccination with Rotarix to prevent gastroenteritis vs. Vaccination with RotaTeq,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,5.00,5.00,Not Stated,Canada,2009,Not Stated
10581,Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: Outcomes of a decision-analytic model,"The incremental cost-effectiveness of transapical transcatheter aortic valve implantation (TAVI) is ill-defined in high-risk patients where aortic valve replacement (AVR) is an option, and has not been ascertained outside a randomized controlled trial.We developed a Markov model to examine the progression of patients between health states, defined as peri- and post-procedural, post-complication, and death. The mean and variance of risks, transition probabilities, utilities and cost of transapical TAVI, high-risk AVR, and medical management were derived from analysis of relevant registries. Outcome and cost were derived from 10,000 simulations. Sensitivity analyses further evaluated the impact of mortality, stroke, and other commonly observed outcomes.In the reference case, both transapical TAVI and high-risk AVR and TAVI were cost-effective when compared to medical management ($44,384/QALY and $42,637/QALY, respectively). Transapical TAVI failed to meet accepted criteria for incremental cost-effectiveness relative to AVR, which was the dominant strategy. In sensitivity analyses, the mortality rates related to the two strategies, the utilities post-AVR and post-transapical TAVI, and the cost of transapical TAVI, were the main drivers of model outcome.Transapical TAVI did not satisfy current metrics of incremental cost-effectiveness relative to high-risk AVR in the reference case. However, it may provide net health benefits at acceptable cost in selected high-risk patients among whom AVR is the standard intervention.",2012-01-14241,23977485,Ann Cardiothorac Surg,Hemal Gada,2012,1 / 2,145-55,No,23977485,"Hemal Gada; Shikhar Agarwal; Thomas H Marwick; Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: Outcomes of a decision-analytic model, Ann Cardiothorac Surg, ; 1(2):2225-319X; 145-55",QALY,United States of America,Not Stated,Not Stated,Transapical transcatheter aortic valve implantation vs. Aortic valve replacement,Not Stated,Not Stated,65 Years,"Female, Male",Full,Lifetime,5.00,5.00,-2500,United States,2012,-2818.14
10582,Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: Outcomes of a decision-analytic model,"The incremental cost-effectiveness of transapical transcatheter aortic valve implantation (TAVI) is ill-defined in high-risk patients where aortic valve replacement (AVR) is an option, and has not been ascertained outside a randomized controlled trial.We developed a Markov model to examine the progression of patients between health states, defined as peri- and post-procedural, post-complication, and death. The mean and variance of risks, transition probabilities, utilities and cost of transapical TAVI, high-risk AVR, and medical management were derived from analysis of relevant registries. Outcome and cost were derived from 10,000 simulations. Sensitivity analyses further evaluated the impact of mortality, stroke, and other commonly observed outcomes.In the reference case, both transapical TAVI and high-risk AVR and TAVI were cost-effective when compared to medical management ($44,384/QALY and $42,637/QALY, respectively). Transapical TAVI failed to meet accepted criteria for incremental cost-effectiveness relative to AVR, which was the dominant strategy. In sensitivity analyses, the mortality rates related to the two strategies, the utilities post-AVR and post-transapical TAVI, and the cost of transapical TAVI, were the main drivers of model outcome.Transapical TAVI did not satisfy current metrics of incremental cost-effectiveness relative to high-risk AVR in the reference case. However, it may provide net health benefits at acceptable cost in selected high-risk patients among whom AVR is the standard intervention.",2012-01-14241,23977485,Ann Cardiothorac Surg,Hemal Gada,2012,1 / 2,145-55,No,23977485,"Hemal Gada; Shikhar Agarwal; Thomas H Marwick; Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: Outcomes of a decision-analytic model, Ann Cardiothorac Surg, ; 1(2):2225-319X; 145-55",QALY,United States of America,Not Stated,Not Stated,Transapical transcatheter aortic valve implantation vs. Medical management,Not Stated,Not Stated,65 Years,"Female, Male",Full,Lifetime,5.00,5.00,34174.7,United States,2012,38523.6
10583,Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: Outcomes of a decision-analytic model,"The incremental cost-effectiveness of transapical transcatheter aortic valve implantation (TAVI) is ill-defined in high-risk patients where aortic valve replacement (AVR) is an option, and has not been ascertained outside a randomized controlled trial.We developed a Markov model to examine the progression of patients between health states, defined as peri- and post-procedural, post-complication, and death. The mean and variance of risks, transition probabilities, utilities and cost of transapical TAVI, high-risk AVR, and medical management were derived from analysis of relevant registries. Outcome and cost were derived from 10,000 simulations. Sensitivity analyses further evaluated the impact of mortality, stroke, and other commonly observed outcomes.In the reference case, both transapical TAVI and high-risk AVR and TAVI were cost-effective when compared to medical management ($44,384/QALY and $42,637/QALY, respectively). Transapical TAVI failed to meet accepted criteria for incremental cost-effectiveness relative to AVR, which was the dominant strategy. In sensitivity analyses, the mortality rates related to the two strategies, the utilities post-AVR and post-transapical TAVI, and the cost of transapical TAVI, were the main drivers of model outcome.Transapical TAVI did not satisfy current metrics of incremental cost-effectiveness relative to high-risk AVR in the reference case. However, it may provide net health benefits at acceptable cost in selected high-risk patients among whom AVR is the standard intervention.",2012-01-14241,23977485,Ann Cardiothorac Surg,Hemal Gada,2012,1 / 2,145-55,No,23977485,"Hemal Gada; Shikhar Agarwal; Thomas H Marwick; Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: Outcomes of a decision-analytic model, Ann Cardiothorac Surg, ; 1(2):2225-319X; 145-55",QALY,United States of America,Not Stated,Not Stated,Aortic valve replacement vs. Medical management,Not Stated,64 Years,19 Years,"Female, Male",Full,Lifetime,5.00,5.00,33311.77,United States,2012,37550.86
10584,Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran,"Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-utility from the Iranian healthcare perspectives of 4DMDs relative to symptom management alone in patients with relapsing-remitting multiple sclerosis using evidence from long-term published studies.A Markov model was developed with patients transitioning through health states based on Kurtzke's expanded disability status scale.Patient costs included drug costs, other medical and lost worker productivity costs. Patient quality of life was considered in the form of utilities. Costs were valued in 2011 USD, and were discounted at 7.2% per annum. Various parameters and assumptions were tested in sensitivity analyses.Total costs per patient over the time horizon of a patient's lifetime were estimated at 20285, 144194, 299279, 251255 and 69796 USD for symptom management, Avonex, Betaferon, Rebif and CinnoVex, respectively. As a result, the incremental cost per quality adjusted life years (QALY) for patients receiving Avonex, Betaferon, Rebif and CinnoVex was 607397, 1374355, 1166515 and 1010429 USD, respectively, when compared with symptom management. The results were sensitive to changes in time horizon, disease progression and drug costs.DMDs in relapsing-remitting MS patients was associated with increased benefits compared with symptom management, albeit at higher costs. Because patients receiving Avonex incurred slightly higher QALYs than patients receiving other DMDs, treatment with Avonex dominates other DMDs in Iran.",2012-01-14715,24250871,Iran J Neurol,Ali Imani,2012,11 / 3,87-90,No,24250871,"Ali Imani; Mina Golestani; Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran, Iran J Neurol, ; 11(3):2008-384X; 87-90",QALY,Iran,Not Stated,Not Stated,CinnoVex vs. Symptom management,Not Stated,Not Stated,19 Years,Not Stated,Full,Lifetime,7.20,7.20,1010429,United States,2011,1162582.48
10585,Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran,"Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-utility from the Iranian healthcare perspectives of 4DMDs relative to symptom management alone in patients with relapsing-remitting multiple sclerosis using evidence from long-term published studies.A Markov model was developed with patients transitioning through health states based on Kurtzke's expanded disability status scale.Patient costs included drug costs, other medical and lost worker productivity costs. Patient quality of life was considered in the form of utilities. Costs were valued in 2011 USD, and were discounted at 7.2% per annum. Various parameters and assumptions were tested in sensitivity analyses.Total costs per patient over the time horizon of a patient's lifetime were estimated at 20285, 144194, 299279, 251255 and 69796 USD for symptom management, Avonex, Betaferon, Rebif and CinnoVex, respectively. As a result, the incremental cost per quality adjusted life years (QALY) for patients receiving Avonex, Betaferon, Rebif and CinnoVex was 607397, 1374355, 1166515 and 1010429 USD, respectively, when compared with symptom management. The results were sensitive to changes in time horizon, disease progression and drug costs.DMDs in relapsing-remitting MS patients was associated with increased benefits compared with symptom management, albeit at higher costs. Because patients receiving Avonex incurred slightly higher QALYs than patients receiving other DMDs, treatment with Avonex dominates other DMDs in Iran.",2012-01-14715,24250871,Iran J Neurol,Ali Imani,2012,11 / 3,87-90,No,24250871,"Ali Imani; Mina Golestani; Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran, Iran J Neurol, ; 11(3):2008-384X; 87-90",QALY,Iran,Not Stated,Not Stated,Rebif (interferon beta-1a) vs. Symptom management,Not Stated,Not Stated,19 Years,Not Stated,Full,Lifetime,7.20,7.20,1166515,United States,2011,1342172.38
10586,Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran,"Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-utility from the Iranian healthcare perspectives of 4DMDs relative to symptom management alone in patients with relapsing-remitting multiple sclerosis using evidence from long-term published studies.A Markov model was developed with patients transitioning through health states based on Kurtzke's expanded disability status scale.Patient costs included drug costs, other medical and lost worker productivity costs. Patient quality of life was considered in the form of utilities. Costs were valued in 2011 USD, and were discounted at 7.2% per annum. Various parameters and assumptions were tested in sensitivity analyses.Total costs per patient over the time horizon of a patient's lifetime were estimated at 20285, 144194, 299279, 251255 and 69796 USD for symptom management, Avonex, Betaferon, Rebif and CinnoVex, respectively. As a result, the incremental cost per quality adjusted life years (QALY) for patients receiving Avonex, Betaferon, Rebif and CinnoVex was 607397, 1374355, 1166515 and 1010429 USD, respectively, when compared with symptom management. The results were sensitive to changes in time horizon, disease progression and drug costs.DMDs in relapsing-remitting MS patients was associated with increased benefits compared with symptom management, albeit at higher costs. Because patients receiving Avonex incurred slightly higher QALYs than patients receiving other DMDs, treatment with Avonex dominates other DMDs in Iran.",2012-01-14715,24250871,Iran J Neurol,Ali Imani,2012,11 / 3,87-90,No,24250871,"Ali Imani; Mina Golestani; Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran, Iran J Neurol, ; 11(3):2008-384X; 87-90",QALY,Iran,Not Stated,Not Stated,Betaferon (interferon beta-1b) vs. Symptom management,Not Stated,Not Stated,19 Years,Not Stated,Full,Lifetime,7.20,7.20,1374355,United States,2011,1581309.56
10587,Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran,"Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-utility from the Iranian healthcare perspectives of 4DMDs relative to symptom management alone in patients with relapsing-remitting multiple sclerosis using evidence from long-term published studies.A Markov model was developed with patients transitioning through health states based on Kurtzke's expanded disability status scale.Patient costs included drug costs, other medical and lost worker productivity costs. Patient quality of life was considered in the form of utilities. Costs were valued in 2011 USD, and were discounted at 7.2% per annum. Various parameters and assumptions were tested in sensitivity analyses.Total costs per patient over the time horizon of a patient's lifetime were estimated at 20285, 144194, 299279, 251255 and 69796 USD for symptom management, Avonex, Betaferon, Rebif and CinnoVex, respectively. As a result, the incremental cost per quality adjusted life years (QALY) for patients receiving Avonex, Betaferon, Rebif and CinnoVex was 607397, 1374355, 1166515 and 1010429 USD, respectively, when compared with symptom management. The results were sensitive to changes in time horizon, disease progression and drug costs.DMDs in relapsing-remitting MS patients was associated with increased benefits compared with symptom management, albeit at higher costs. Because patients receiving Avonex incurred slightly higher QALYs than patients receiving other DMDs, treatment with Avonex dominates other DMDs in Iran.",2012-01-14715,24250871,Iran J Neurol,Ali Imani,2012,11 / 3,87-90,No,24250871,"Ali Imani; Mina Golestani; Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran, Iran J Neurol, ; 11(3):2008-384X; 87-90",QALY,Iran,Not Stated,Not Stated,Avonex (interferon beta-1a) vs. Symptom management,Not Stated,Not Stated,19 Years,Not Stated,Full,Lifetime,7.20,7.20,607397,United States,2011,698860.69
10588,Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective,"To evaluate, from the perspective of the Brazilian public health care system, the cost-effectiveness of lapatinib plus capecitabine (LAP/CAP) versus capecitabine alone (CAP) or trastuzumab plus capecitabine (TRAST/CAP) in the treatment of women with human epidermal growth factor receptor-2-positive metastatic breast cancer previously treated with trastuzumab.An economic model was developed to compare costs and clinical outcomes over a 5-year time horizon. Both costs and outcomes were discounted at a 5% rate, in accordance with Brazilian pharmacoeconomic guidelines. Clinical inputs were determined using indirect treatment comparisons. Costs were derived from public reimbursement databases and reported in 2010 Brazilian real (R$1 = USD$0.52). Clinical outcomes included progression-free survival years (PFYs), life-years (LYs) and quality-adjusted life-years (QALYs). The economic outcome was the incremental cost per LY, PFY, or QALY gained. The impact of variations in individual inputs (eg, drug cost, drug effectiveness) was examined using one-way sensitivity analyses. Overall model robustness was tested using probabilistic sensitivity analyses, varying the ranges of all input parameters within their standard distributions.Expected cost per patient was R$41,195 for CAP, R$95,256 for LAP/CAP, and R$113,686 for TRAST/CAP. Respective LYs were 1.406, 1.695, and 1.465; PFYs were 0.473, 0.711, and 0.612; and QALYS were 0.769, 0.958, and 0.827. LAP/CAP dominated TRAST/CAP for all outcomes. Incremental cost-effectiveness ratios of LAP/CAP over CAP were R$186,563 for LYs, R$226,403 for PFYs, and R$284,864 for QALYs. Results remained unchanged in one-way sensitivity analyses. In probabilistic analyses, LAP/CAP was dominant over TRAST/CAP in 93.5% of simulations.LAP/CAP increases survival for women with human epidermal growth factor receptor-2-positive metastatic breast cancer. LAP/CAP is cost-effective against TRAST/CAP (ie, produces more benefits at a lower cost) and can be considered cost-effective over CAP at a willingness-to-pay of about R$290,000 (US$151,000) per QALY gained.",2012-01-14930,24367204,Breast Cancer (Dove Med Press),Marcio Machado,2012,4 /,173-82,No,24367204,"Marcio Machado; Thomas R Einarson; Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective, Breast Cancer (Dove Med Press), ; 4():1179-1314; 173-82",QALY,Brazil,Not Stated,Not Stated,Lapatinib plus capecitabine vs. Trastuzumab plus capecitabine (TRAST/CAP),Not Stated,Not Stated,19 Years,Female,Full,5 Years,5.00,5.00,-140687.03,Brazil,2010,-94957.59
10589,Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective,"To evaluate, from the perspective of the Brazilian public health care system, the cost-effectiveness of lapatinib plus capecitabine (LAP/CAP) versus capecitabine alone (CAP) or trastuzumab plus capecitabine (TRAST/CAP) in the treatment of women with human epidermal growth factor receptor-2-positive metastatic breast cancer previously treated with trastuzumab.An economic model was developed to compare costs and clinical outcomes over a 5-year time horizon. Both costs and outcomes were discounted at a 5% rate, in accordance with Brazilian pharmacoeconomic guidelines. Clinical inputs were determined using indirect treatment comparisons. Costs were derived from public reimbursement databases and reported in 2010 Brazilian real (R$1 = USD$0.52). Clinical outcomes included progression-free survival years (PFYs), life-years (LYs) and quality-adjusted life-years (QALYs). The economic outcome was the incremental cost per LY, PFY, or QALY gained. The impact of variations in individual inputs (eg, drug cost, drug effectiveness) was examined using one-way sensitivity analyses. Overall model robustness was tested using probabilistic sensitivity analyses, varying the ranges of all input parameters within their standard distributions.Expected cost per patient was R$41,195 for CAP, R$95,256 for LAP/CAP, and R$113,686 for TRAST/CAP. Respective LYs were 1.406, 1.695, and 1.465; PFYs were 0.473, 0.711, and 0.612; and QALYS were 0.769, 0.958, and 0.827. LAP/CAP dominated TRAST/CAP for all outcomes. Incremental cost-effectiveness ratios of LAP/CAP over CAP were R$186,563 for LYs, R$226,403 for PFYs, and R$284,864 for QALYs. Results remained unchanged in one-way sensitivity analyses. In probabilistic analyses, LAP/CAP was dominant over TRAST/CAP in 93.5% of simulations.LAP/CAP increases survival for women with human epidermal growth factor receptor-2-positive metastatic breast cancer. LAP/CAP is cost-effective against TRAST/CAP (ie, produces more benefits at a lower cost) and can be considered cost-effective over CAP at a willingness-to-pay of about R$290,000 (US$151,000) per QALY gained.",2012-01-14930,24367204,Breast Cancer (Dove Med Press),Marcio Machado,2012,4 /,173-82,No,24367204,"Marcio Machado; Thomas R Einarson; Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective, Breast Cancer (Dove Med Press), ; 4():1179-1314; 173-82",QALY,Brazil,Not Stated,Not Stated,Lapatinib plus capecitabine vs. Capecitabine alone,Not Stated,Not Stated,19 Years,Female,Full,5 Years,5.00,5.00,284864,Brazil,2010,192270.74
10590,Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps,"The growing understanding of the use of biomarkers in Alzheimer''s disease (AD) may enable physicians to make more accurate and timely diagnoses. Florbetaben, a beta-amyloid tracer used with positron emission tomography (PET), is one of these diagnostic biomarkers. This analysis was undertaken to explore the potential value of florbetaben PET in the diagnosis of AD among patients with suspected dementia and to identify key data that are needed to further substantiate its value. A discrete event simulation was developed to conduct exploratory analyses from both US payer and societal perspectives. The model simulates the lifetime course of disease progression for individuals, evaluating the impact of their patient management from initial diagnostic work-up to final diagnosis. Model inputs were obtained from specific analyses of a large longitudinal dataset from the New England Veterans Healthcare System and supplemented with data from public data sources and assumptions. The analyses indicate that florbetaben PET has the potential to improve patient outcomes and reduce costs under certain scenarios. Key data on the use of florbetaben PET, such as its influence on time to confirmation of final diagnosis, treatment uptake, and treatment persistency, are unavailable and would be required to confirm its value.",2012-01-19350,23326754,Int J Alzheimers Dis,Shien Guo,2012,2012 /,548157,No,23326754,"Shien Guo; Denis Getsios; Luis Hernandez; Kelly Cho; Elizabeth Lawler; Arman Altincatal; Stephan Lanes; Michael Blankenburg; Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps, Int J Alzheimers Dis, ; 2012():2090-0252; 548157",QALY,United States of America,Not Stated,Not Stated,Florbetaben positron emission tomography for early diagnosis of Alzheimer's vs. Standard/Usual Care,Not Stated,Not Stated,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,-48214.81,United States,2011,-55475.15
10591,Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps,"The growing understanding of the use of biomarkers in Alzheimer''s disease (AD) may enable physicians to make more accurate and timely diagnoses. Florbetaben, a beta-amyloid tracer used with positron emission tomography (PET), is one of these diagnostic biomarkers. This analysis was undertaken to explore the potential value of florbetaben PET in the diagnosis of AD among patients with suspected dementia and to identify key data that are needed to further substantiate its value. A discrete event simulation was developed to conduct exploratory analyses from both US payer and societal perspectives. The model simulates the lifetime course of disease progression for individuals, evaluating the impact of their patient management from initial diagnostic work-up to final diagnosis. Model inputs were obtained from specific analyses of a large longitudinal dataset from the New England Veterans Healthcare System and supplemented with data from public data sources and assumptions. The analyses indicate that florbetaben PET has the potential to improve patient outcomes and reduce costs under certain scenarios. Key data on the use of florbetaben PET, such as its influence on time to confirmation of final diagnosis, treatment uptake, and treatment persistency, are unavailable and would be required to confirm its value.",2012-01-19350,23326754,Int J Alzheimers Dis,Shien Guo,2012,2012 /,548157,No,23326754,"Shien Guo; Denis Getsios; Luis Hernandez; Kelly Cho; Elizabeth Lawler; Arman Altincatal; Stephan Lanes; Michael Blankenburg; Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps, Int J Alzheimers Dis, ; 2012():2090-0252; 548157",QALY,United States of America,Not Stated,Not Stated,Florbetaben positron emission tomography for early diagnosis of Alzheimer's vs. Standard/Usual Care,Not Stated,Not Stated,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,-379633.34,United States,2011,-436799.69
10594,Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States,"BACKGROUND: Recent clinical trial data have demonstrated that 3 years vs 1 year of adjuvant imatinib therapy for patients with surgically resected Kit+ Gastrointestinal Stromal Tumors (GIST) leads to a significant improvement in recurrence-free survival and overall survival. This study assesses the cost-effectiveness of treating patients with 3 years vs 1 year of imatinib from a US payer''s perspective. METHODS: A Markov model was developed to predict GIST recurrence and treatment costs. Patients enter the model after surgery and transition among three health states: free of recurrence, recurrence, and death. Recurrence, mortality, costs, and utilities were derived from clinical trial and published literature. Expected costs and quality-adjusted life years (QALYs) were estimated and discounted at 3%/year. Deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Patients receiving 3 years of imatinib had higher QALYs (8.53 vs 7.18) than those receiving 1 year of imatinib. Total lifetime per-patient cost was $302,100 for 3 years vs $217,800 for 1 year of imatinib. Incremental cost effectiveness ratio of 3 years vs 1 year of imatinib was $62,600/QALY. Model results were sensitive to long-term rate of GIST recurrence (beyond 5 years) and cost of imatinib. At a threshold of $100,000/QALY, 3 years vs 1 year of imatinib was cost-effective in 100% of simulations. LIMITATIONS: The model is a simplified representation of disease natural history and may not account for all possible health states and complications associated with disease. Resource utilization on treatment was estimated using the resource use data from previous trials, therefore calculated medical costs might be over-estimated compared to the real-world setting. CONCLUSIONS: Model results suggest that treatment with 3 years vs 1 year of imatinib is cost-effective at a $100,000/QALY threshold. Clinical and economic results suggest treating surgically resected Kit+ GIST patients with 3 years of imatinib would result in improved quality-adjusted survival.",2013-01-09443,22762291,J Med Econ,Myrlene Sanon,2013,16 / 1,150-159,Yes,22762291,"Myrlene Sanon; Douglas C A Taylor; Anju Parthan; John Coombs; Marc Paolantonio; Medha Sasane; Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States, J Med Econ, 2013; 16(1):1369-6998; 150-159",QALY,United States of America,Not Stated,Not Stated,3 years of imatinib (400mg/day administered orally) vs. 1 year of imatinib (400mg/day administered orally),Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,62600,United States,2010,74300.04
10595,A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom,"OBJECTIVE: There is limited information regarding the cost-effectiveness of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis in the UK. Using a UK National Health Service (NHS) perspective and final results of the Dialysis Clinical Outcomes Revisited (DCOR) study, an evaluation was performed to determine the cost-effectiveness of sevelamer compared to calcium-based phosphate binders for the first-line treatment of hyperphosphatemia in CKD patients on dialysis. METHODS: A Markov model was developed to estimate life years, quality-adjusted life years (QALYs), costs, incremental cost per life year (LY) gained, and QALY gained. Treatment-specific overall survival up to 44 months, hospitalizations, and resource utilization were derived from the DCOR study. Survival was extrapolated to a lifetime horizon using Weibull regression analysis. Unit costs and utility estimates specific to the UK were obtained from the published literature. Sub-group analyses were conducted based on data reported from the DCOR study for increasing age cut-points. Outcomes and costs were modeled for a lifetime horizon. RESULTS: In the base case analysis, the use of sevelamer resulted in a gain of approximately 0.73 LYs and 0.44 QALYs per patient (discounted at 3.5% per year). Total per-patient costs were higher for sevelamer, resulting in an incremental cost of pound22,157 per QALY gained and pound13,427 per LY gained (in pound2009). Increasingly favorable cost per QALY ratios were observed with increasing age cut-points, ranging from pound15,864 for patients >/=45 to pound13,296 for patients >/=65 years of age. Results were most sensitive to assumptions regarding overall survival and the inclusion of dialysis costs. Key limitations of the analysis included the use of non-UK trial data for survival and hospitalizations, and the exclusion of quality-of-life impacts associated with hospitalization. CONCLUSIONS: In CKD patients receiving dialysis, treatment of hyperphosphatemia with sevelamer offers good value for money compared with calcium-based binders.",2013-01-09574,22857538,J Med Econ,Lisa Bernard,2013,16 / 1,1-9,Yes,22857538,"Lisa Bernard; David Mendelssohn; Elizabeth Dunn; Colin Hutchison; Daniel T Grima; A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom, J Med Econ, 2013; 16(1):1369-6998; 1-9",QALY,United States of America,Not Stated,Not Stated,Sevelamar carbonate (6.9g/day) vs. Calcium based binders (CBB) - [Calcium acetate 5.3g/day OR Calcium carbonate 4.9g/day),receiving dialysis for at least three (3) months,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,22157,United Kingdom,2009,38702.44
10596,Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis,"OBJECTIVE: Denosumab has been approved in the US for skeletal-related event (SRE) prevention in bone-metastatic prostate cancer on the basis of a phase III clinical trial in which denosumab reduced SREs relative to zoledronic acid. Overall survival, disease progression, and serious adverse events did not differ significantly between groups. This analysis assessed the cost-effectiveness of denosumab vs zoledronic acid in bone-metastatic prostate cancer from a US payer perspective. METHODS: A literature-based Markov model, wherein inputs were selected to reproduce clinical trial outcomes, was developed to estimate the survival, quality-adjusted life-years (QALYs), number and costs of SREs, and drug and administration costs for patients receiving denosumab or zoledronic acid over 27 months. QALYs were estimated by assigning health-state utilities. SRE-related costs and utilities were literature-based. Outcomes were discounted 3% per annum, and model robustness was tested via scenario, univariate, and probabilistic sensitivity analyses. RESULTS: Denosumab resulted in fewer estimated SREs (-0.241; 1.036 vs 1.277), more QALYs (0.0074; 0.9306 vs 0.9232), and lower SRE-related costs (-$2340; $8824 vs $11,164), but higher drug-related costs ($10,181; $23,144 vs $12,963) and total costs ($7841; $31,968 vs $24,127) vs zoledronic acid. The base case estimated cost per QALY-gained was $1,058,741. CONCLUSION: This analysis was limited by the restricted availability of clinical data and the need to use projection methods beyond the trial time frame. However, a wide range of scenarios predicted denosumab to have an incremental cost/QALY gained above what may be considered acceptable value for money in the US. This raises important questions regarding the pharmacoeconomic value of denosumab in bone-metastatic prostate cancer.",2013-01-09605,22870908,J Med Econ,Sonya J Snedecor,2013,16 / 1,19-29,Yes,22870908,"Sonya J Snedecor; John A Carter; Satyin Kaura; Marc F Botteman; Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis, J Med Econ, 2013; 16(1):1369-6998; 19-29",QALY,United States of America,Not Stated,Not Stated,Denosumab (120mg monthly) vs. Zoledronic acid (4mg monthly),Not Stated,Not Stated,19 Years,Male,Full,"27 Months, 60 months",3.00,3.00,1058741,United States,2010,1256621.31
10597,Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting,"OBJECTIVE: The 21-gene assay (Oncotype DX Breast Cancer Test (Genomic Health Inc., Redwood City, CA)) is a well validated test that predicts the likelihood of adjuvant chemotherapy benefit and the 10-year risk of distant recurrence in patients with ER+, HER2- early-stage breast cancer. The aim of this analysis was to evaluate the cost-effectiveness of using the assay to inform adjuvant chemotherapy decisions in Germany. METHODS: A Markov model was developed to make long-term projections of distant recurrence, survival, quality-adjusted life expectancy, and direct costs for patients with ER+, HER2-, node-negative, or up to 3 node-positive early-stage breast cancer. Scenarios using conventional diagnostic procedures or the 21-gene assay to inform treatment recommendations for adjuvant chemotherapy were modeled based on a prospective, multi-center trial in 366 patients. Transition probabilities and risk adjustment were based on published landmark trials. Costs (2011 Euros (euro)) were estimated from a sick fund perspective based on resource use in patients receiving chemotherapy. Future costs and clinical benefits were discounted at 3% annually. RESULTS: The 21-gene assay was projected to increase mean life expectancy by 0.06 years and quality-adjusted life expectancy by 0.06 quality-adjusted life years (QALYs) compared with current clinical practice over a 30-year time horizon. Clinical benefits were driven by optimized allocation of adjuvant chemotherapy. Costs from a healthcare payer perspective were lower with the 21-gene assay by approximately euro561 vs standard of care. Probabilistic sensitivity analysis indicated that there was an 87% probability that the 21-gene assay would be dominant (cost and life saving) to standard of care. LIMITATIONS: Country-specific data on the risk of distant recurrence and quality-of-life were not available. CONCLUSIONS: Guiding decision-making on adjuvant chemotherapy using the 21-gene assay was projected to improve survival, quality-adjusted life expectancy, and be cost saving vs the current standard of care women with ER+, HER2- early-stage breast cancer.",2013-01-09738,22966753,J Med Econ,J U Blohmer,2013,16 / 1,30-40,Yes,22966753,"J U Blohmer; M Rezai; S Kummel; T Kuhn; M Warm; K Friedrichs; A Benkow; W J Valentine; W Eiermann; Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting, J Med Econ, 2013; 16(1):1369-6998; 30-40",QALY,Germany,Not Stated,Not Stated,Therapy based on 21-gene assay recurrence score (RS) {Oncotype DX Breast Cancer Test} vs. Standard/Usual care,Not Stated,Not Stated,19 Years,Female,Full,30 Years,3.00,3.00,-8014.29,Euro,2011,-12831.88
10598,Cost-effectiveness of single-level anterior cervical discectomy and fusion five years after surgery,"STUDY DESIGN: Longitudinal cohort. OBJECTIVE.: The purpose of this study is to determine the cost per quality-adjusted life year (cost/QALY) gained for single-level instrumented anterior cervical discectomy and fusion (ACDF) over 5 years. SUMMARY OF BACKGROUND DATA: Economic value is an increasingly important component of health care policy decision making. METHODS: Control patients who had undergone ACDF with complete 5-year follow-up data who were part of the Investigational Device Exemption trials for cervical disc arthroplasty were identified. Direct costs for each intervention reported as part of the trial were determined using the 2012 Medicare Fee schedule. Health utility was determined using the Short Form-6D, calculated by transformation from the Short Form-36. RESULTS: There were 352 patients (182 women, 170 men), mean age was 44.6 years (22-73 yr). Cost per patient for the index ACDF was $15,714. Over 5 years, 41 repeat ACDFs, 15 posterior fusions, 6 foraminotomies, 2 implant removals, 2 hematoma evacuations, and 1 esophageal fistula repair were performed. Mean QALY gained in each year of follow-up was 0.16, 0.18, 0.17, 0.18, and 0.18 for a cumulative 0.88 QALY gain over 5 years. The resultant cost/QALY gain at 1 year was $104,831; $53,074 at year 2; $37,717 at year 3; $28,383 at year 4; and $23,460 at year 5. In this cohort, 11 nerve releases and 26 rotator cuff repairs were done within 5 years after the index ACDF. Subanalysis to include upper extremity procedures was performed. The cost/QALY gained at 1 year including upper extremity procedures was $106,256; $54,622 at year 2; $38,836 at year 3; $29,454 at year 4; and $24,479 at year 5. CONCLUSION: Increasing health care costs call for demonstration of cost-effectiveness in order to justify payment for interventions, including ACDFs. This study indicates that at 5-year follow-up, single-level instrumented ACDF is both effective and durable resulting in a favorable cost/QALY gained as compared to other widely accepted health care interventions.",2013-01-09770,22986842,Spine (Phila Pa 1976) Spine (Phila Pa 1976),Leah Y Carreon,2013,38 / 6,,No,22986842,"Leah Y Carreon; Paul A Anderson; Vincent C Traynelis; Praveen V Mummaneni; Steven D Glassman; Cost-effectiveness of single-level anterior cervical discectomy and fusion five years after surgery, Spine (Phila Pa 1976) Spine (Phila Pa 1976) , ; 38(6):1528-1159",QALY,United States of America,Not Stated,Not Stated,Single-level anterior disectomy and fusion (ACDF) using allograft with an ATLANTIS plate vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,5 Years,Not Stated,Not Stated,23477.51,United States,2012,26465.14
10599,Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan,"Many postmenopausal women have osteopenia, a condition characterized by loss of bone mineral density (BMD) that is not as severe as in osteoporosis. The objective of this study was to estimate the cost-effectiveness of alendronate to prevent fractures in osteopenic postmenopausal women without a history of fracture in Japan. An individual simulation model was developed to predict lifetime costs and quality-adjusted life years (QALYs) of 5 years of preventive alendronate therapy versus no preventive therapy. The risk of hip and vertebral fracture associated with age and BMD was derived from epidemiologic studies in Japan. We ran the model with different combinations of age (65, 70, and 75 years), BMD (70%, 75%, and 80% of young adult mean [YAM]), and additional clinical risk factors. For 70-year-old women with a BMD of 70% of the YAM having one of the following risk factors: a family history of hip fracture, high alcohol intake, or current smoking, the incremental cost-effectiveness ratio (ICER) of alendronate was $92,937, $126,251, and $129,067 per QALY, respectively. These results were sensitive to age, BMD, and number of clinical risk factors. Probabilistic sensitivity analysis for the base case showed that in the presence of one, two, and three risk factors, alendronate was cost-effective in 0.2% to 2.6%, 13.1% to 56.1%, and 99.1% of the simulations, respectively, if society is willing to pay $50,000 per QALY. Additional analysis indicated that alendronate can be a good value in osteopenic women if the 10-year probability for a osteoporotic hip or vertebral fracture is more than 26.2%. Our results indicate that whether to treat osteopenia with alendronate should be determined on the basis of age, BMD, and number of clinical risk factors in terms of cost-effectiveness.",2013-01-09777,22991163,J Bone Miner Res,Kensuke Moriwaki,2013,28 / 2,,No,22991163,"Kensuke Moriwaki; Hirotaka Komaba; Shinichi Noto; Shinichiro Yanagisawa; Toru Takiguchi; Hiroki Inoue; Takeshi Toujo; Masafumi Fukagawa; Hideaki E Takahashi; Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan, J Bone Miner Res, 2013 Feb; 28(2):1523-4681",QALY,Japan,Not Stated,Not Stated,5 years of preventive alendronate therapy vs. None,Postmenopausal women aged 70 years with family history of hip fracture and bone mineral density (BMD) of 70% of young adult mean (YAM),Not Stated,65 Years,Female,Full,Lifetime,3.00,3.00,92937,United States,2012,104763.7
10600,Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan,"Many postmenopausal women have osteopenia, a condition characterized by loss of bone mineral density (BMD) that is not as severe as in osteoporosis. The objective of this study was to estimate the cost-effectiveness of alendronate to prevent fractures in osteopenic postmenopausal women without a history of fracture in Japan. An individual simulation model was developed to predict lifetime costs and quality-adjusted life years (QALYs) of 5 years of preventive alendronate therapy versus no preventive therapy. The risk of hip and vertebral fracture associated with age and BMD was derived from epidemiologic studies in Japan. We ran the model with different combinations of age (65, 70, and 75 years), BMD (70%, 75%, and 80% of young adult mean [YAM]), and additional clinical risk factors. For 70-year-old women with a BMD of 70% of the YAM having one of the following risk factors: a family history of hip fracture, high alcohol intake, or current smoking, the incremental cost-effectiveness ratio (ICER) of alendronate was $92,937, $126,251, and $129,067 per QALY, respectively. These results were sensitive to age, BMD, and number of clinical risk factors. Probabilistic sensitivity analysis for the base case showed that in the presence of one, two, and three risk factors, alendronate was cost-effective in 0.2% to 2.6%, 13.1% to 56.1%, and 99.1% of the simulations, respectively, if society is willing to pay $50,000 per QALY. Additional analysis indicated that alendronate can be a good value in osteopenic women if the 10-year probability for a osteoporotic hip or vertebral fracture is more than 26.2%. Our results indicate that whether to treat osteopenia with alendronate should be determined on the basis of age, BMD, and number of clinical risk factors in terms of cost-effectiveness.",2013-01-09777,22991163,J Bone Miner Res,Kensuke Moriwaki,2013,28 / 2,,No,22991163,"Kensuke Moriwaki; Hirotaka Komaba; Shinichi Noto; Shinichiro Yanagisawa; Toru Takiguchi; Hiroki Inoue; Takeshi Toujo; Masafumi Fukagawa; Hideaki E Takahashi; Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan, J Bone Miner Res, 2013 Feb; 28(2):1523-4681",QALY,Japan,Not Stated,Not Stated,5 years of preventive alendronate therapy vs. None,Postmenopausal women aged 70 years with no history of clinical fracture (no risk factors) and bone mineral density (BMD) of 70% of young adult mean (YAM),Not Stated,65 Years,Female,Full,Lifetime,3.00,3.00,227905,United States,2012,256907.07
